<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004888.pub2" GROUP_ID="LIVER" ID="668403021812090541" MERGED_FROM="" MODIFIED="2010-02-17 18:12:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2010-02-17 18:12:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2008-09-01 14:35:51 +0200" MODIFIED_BY="[Empty name]">Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus</TITLE>
<CONTACT>
<PERSON ID="11708" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alfonso</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iorio</LAST_NAME>
<SUFFIX/>
<POSITION>Internal and Vascular Medicine - Hemophilia Centre</POSITION>
<EMAIL_1>iorioa@unipg.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1>Ospedale Santa Maria della Misericordia</ADDRESS_1>
<ADDRESS_2>Località Sant'Andrea delle Fratte</ADDRESS_2>
<CITY>Perugia</CITY>
<ZIP>06126</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 075 578 2309 ext 2765</PHONE_1>
<PHONE_2>+39 348 93 78 046</PHONE_2>
<FAX_1>+39 178 22 18 383</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-02-17 18:11:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="11708" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alfonso</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iorio</LAST_NAME>
<SUFFIX/>
<POSITION>Internal and Vascular Medicine - Hemophilia Centre</POSITION>
<EMAIL_1>iorioa@unipg.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1>Ospedale Santa Maria della Misericordia</ADDRESS_1>
<ADDRESS_2>Località Sant'Andrea delle Fratte</ADDRESS_2>
<CITY>Perugia</CITY>
<ZIP>06126</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 075 578 2309 ext 2765</PHONE_1>
<PHONE_2>+39 348 93 78 046</PHONE_2>
<FAX_1>+39 178 22 18 383</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B5396B7182E26AA2004F1ADAE72B5EF4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Emanuela</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marchesini</LAST_NAME>
<SUFFIX/>
<POSITION>Internal and Vascular Medicine - Hemophilia Centre</POSITION>
<EMAIL_1>manumarchesini@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1>Ospedale Santa Maria della Misericordia</ADDRESS_1>
<ADDRESS_2>Località Sant'Andrea delle Fratte</ADDRESS_2>
<CITY>Perugia</CITY>
<ZIP>06126</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="F48AF30F82E26AA2009C393D2FDD6B25" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tahany</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Awad</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tahany@ctu.rh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 354571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D., Dr.Med.Sci.</SUFFIX>
<POSITION/>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>Gentofte University Hospital</ORGANISATION>
<ADDRESS_1>Niels Andersensvej 65</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hellerup</CITY>
<ZIP>2900</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>31353212</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-02-17 18:11:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="25" MONTH="5" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="8" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-02-17 18:12:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-17 18:12:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="27" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>A peer reviewer acknowledged for comments.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-11-06 15:28:29 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-09-23 13:37:38 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<INTERNAL_SOURCES MODIFIED="2008-09-23 13:37:38 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<SOURCE MODIFIED="2008-09-23 13:37:38 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<NAME>The Cochrane Hepato-Biliary Group</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-17 18:11:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2009-11-10 12:59:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2008-09-01 14:15:18 +0200" MODIFIED_BY="[Empty name]">Antiviral treatment for chronic hepatitis C in patients with HIV infection</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-10 12:59:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>End-stage liver disease due to chronic hepatitis C is the leading cause of death among patients with stable HIV. The recommended treatment for chronic hepatitis C among patients without HIV is peginterferon plus ribavirin. Based on evidence from trials on HIV-negative patients with hepatitis C, the viral genotype, dose of treatment and duration of therapy may affect the treatment response. This review is the first to evaluate the antiviral effect of peginterferon, ribavirin or amantadine administered in different combinations for a patient group, which has not previously been treated for hepatitis C. A total of 14 randomised clinical trials with at total of 2269 patients have been included in this review.The present review suggests that peginterferon plus ribavirin may also be considered if patients have HIV. The dose of peginterferon was similar to that assessed in trials on patients without HIV (180 microgram or 1.5 microgram/kg once weekly), but the dose of ribavirin was somewhat lower in most trials (800 mg daily). There were considerable differences between the trials possibly related to the dose and duration of treatment or the proportion of patients with different hepatitis C virus genotypes. The benefit of treatment was seen when assessing the proportion of patients with a sustained loss of the hepatitis C virus from the blood and the proportion with improved liver biopsies. No significant differences were seen in clinical outcome measures, including mortality (1%, irrespective of treatment). There were several adverse events. Fatal lactic acidosis and liver failure occurred. Other adverse events included anaemia and flu-like symptoms that occurred more frequently among patients receiving peginterferon plus ribavirin. No significant differences were seen regarding the risk of depression, mortality, and progression to cirrhosis or to AIDS. Additional randomised trials are necessary to assess the effect in HIV and HCV co-infected patients of peginterferon plus ribavirin in relation to the duration of therapy, especially in patients with hepatitis C genotype 2 or 3. Additional trials comparing peginterferon plus ribavirin versus interferon plus ribavirin or peginterferon alone do not seem warranted.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-09 22:09:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2009-11-06 15:05:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Antiviral treatment for chronic hepatitis C may be less effective if patients are co-infected with human immunodeficiency virus (HIV).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-09-23 08:05:28 +0200" MODIFIED_BY="Alfonso Iorio">
<P>To assess the benefits and harms of antiviral treatment for chronic hepatitis C in patients with HIV.<BR/>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-11-09 22:08:16 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Trials were identified through manual and electronic searches in <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, the <I>Cochrane Central Register of Controlled Trials</I> <I>(CENTRAL) </I>in <I>The Cochrane Library</I>, <I>MEDLINE</I>, <I>EMBASE, and Science Citation Index Expanded</I>. The last search was May 2009.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-09 22:08:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised trials comparing at least 12 weeks of any anti-HCV treatment versus another treatment regimen or no treatment. Included patients had chronic hepatitis C and stable HIV irrespective of previous antiviral therapy.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio">
<P>Data extraction and assessment of risk of bias were done in duplicate. Analysis was by intention-to-treat. <BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-09 22:09:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Fourteen trials were included. None of the included 2269 patients were previously treated for chronic hepatitis C. Peginterferon (either 2a, 180 microgram, or 2b, 1.5 microgram/kg, once weekly) plus ribavirin was more effective in achieving end of treatment and sustained virological response compared with interferon plus ribavirin (5 trials, 1340 patients) or peginterferon (2 trials, 714 patients). The benefit of peginterferon plus ribavirin was seen irrespective of HCV genotype although patients with genotype 1 or 4 had lower response rates (27%) than patients with genotype 2 or 3 (56%). The remaining trials compared different treatment regimens in patients who were treatment naive or had no virological response after three months of treatment, but overall they had not enough power to show any effect of increasing the dose of interferon or adding both amantadine or ribavirin. The overall mortality was 23/2111 patients with no significant differences between treatment regimens. Treatment increased the risk of adverse events including anaemia and flu-like symptoms, and several serious adverse events occurred including fatal lactic acidosis, liver failure, and suicide due to depression.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-10-02 13:00:55 +0200" MODIFIED_BY="Alfonso Iorio">
<P>Peginterferon plus ribavirin may be considered a treatment for patients with chronic hepatitis C and stable HIV who have not received treatment for hepatitis C as the intervention may clear the blood of HCV RNA. Supporting evidence comes mainly from the analysis of this non-validated surrogate outcome assessed in comparisons against other antiviral treatments. There is no evidence on treatment of patients who have relapsed or did not respond to previous therapy. Careful monitoring of adverse events is warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-11 16:15:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2009-11-11 16:10:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>World-wide, the prevalence of hepatitis C and human immunodeficiency virus (HIV) coinfection ranges from about 10% to 50% (<LINK REF="REF-Mohsen-2002" TYPE="REFERENCE">Mohsen 2002</LINK>). The prevalence of hepatitis C and HIV co-infection is especially high among intravenous drug abusers and patients who have received contaminated blood or blood products (<LINK REF="REF-Daar-2001" TYPE="REFERENCE">Daar 2001</LINK>; <LINK REF="REF-Mohsen-2002" TYPE="REFERENCE">Mohsen 2002</LINK>). After the introduction of highly active antiretroviral therapy (HAART) in 1996, the prognosis of patients with HIV improved considerably (<LINK REF="REF-Rockstroh-2004" TYPE="REFERENCE">Rockstroh 2004</LINK>). Since then, hepatitis C has become one of the main causes of death among patients with stable HIV (<LINK REF="REF-Rodriguez-2001" TYPE="REFERENCE">Rodriguez 2001</LINK>; <LINK REF="REF-Soriano-2002" TYPE="REFERENCE">Soriano 2002</LINK>). The course of HCV infection in HIV co-infected patients appears to be more severe. After acute HCV infection 14% to 45% of individuals spontaneously clear the virus, while HCV clearance occurs in only 5% of HIV co-infected persons, and less often in those with lower CD4 cell counts (<LINK REF="REF-Alter-1992" TYPE="REFERENCE">Alter 1992</LINK>; <LINK REF="REF-Villano-1999" TYPE="REFERENCE">Villano 1999</LINK>; <LINK REF="REF-Thomas--2000" TYPE="REFERENCE">Thomas 2000</LINK>). Clinical studies suggest that HIV worsens the course of chronic hepatitis C (<LINK REF="REF-Waldrep-2000" TYPE="REFERENCE">Waldrep 2000</LINK>; <LINK REF="REF-Graham-2001" TYPE="REFERENCE">Graham 2001</LINK>; <LINK REF="REF-Rodriguez-2001" TYPE="REFERENCE">Rodriguez 2001</LINK>). Coinfection is associated with higher HCV RNA levels compared to HCV patients (<LINK REF="REF-Eyster-1994" TYPE="REFERENCE">Eyster 1994</LINK>; <LINK REF="REF-Marcellin-1994" TYPE="REFERENCE">Marcellin 1994</LINK>; <LINK REF="REF-Soto-1997" TYPE="REFERENCE">Soto 1997</LINK>; <LINK REF="REF-Di-Martino-2001" TYPE="REFERENCE">Di Martino 2001</LINK>; <LINK REF="REF-Serfaty-2001" TYPE="REFERENCE">Serfaty 2001</LINK>).</P>
<P>Among patients with chronic hepatitis C, the proportion who are able to clear the hepatitis C virus spontaneously is negligible, both for patients without HIV and patients with HIV coinfection (<LINK REF="REF-Poynard-1996" TYPE="REFERENCE">Poynard 1996</LINK>; <LINK REF="REF-Mohsen-2002" TYPE="REFERENCE">Mohsen 2002</LINK>). Liver fibrosis progression is accelerated in HIV coinfected patients, with a more rapid progression to cirrhosis compared with HCV infected individuals (<LINK REF="REF-Soto-1997" TYPE="REFERENCE">Soto 1997</LINK>; <LINK REF="REF-Benhamou-1999" TYPE="REFERENCE">Benhamou 1999</LINK>). The risk of death in HIV-coinfected patients is substantially higher compared to those with chronic HCV alone (risk ratio (RR), 2.26; 95% CI 1.51 to 3.38) (<LINK REF="REF-Pineda-2005" TYPE="REFERENCE">Pineda 2005</LINK>). In a meta-analysis of trials comparing interferon with placebo in 6545 HCV patients without HIV infection the odd ratio was 4.6 (95% CI 1.53 to 13.85) for sustained virological response and 9.22 (95% CI 5.69 to 14.94) for histologic improvement (<LINK REF="REF-Myers-2002" TYPE="REFERENCE">Myers 2002</LINK>). A meta-analysis of trials comparing interferon plus ribavirin with interferon monotherapy in 9991 patients with chronic HCV without HIV infection found a risk ratio of 0.73 (95% CI 0.71 to 0.75) for sustained virological response and 0.46 (95% CI 0.22 to 0.96) for morbidity plus mortality (<LINK REF="REF-Brok-2005" TYPE="REFERENCE">Brok 2005</LINK>). In most trials, a higher rate of sustained virological response was observed in genotype 2 and 3 infected patients as compared to genotype 1 and 4, but without any statistically significant effect at meta-regression (<LINK REF="REF-Brok-2005" TYPE="REFERENCE">Brok 2005</LINK>). Although several patients relapsed within the first six months after treatment, the proportion of patients with a six months sustained virological response was about 40%. In comparison, less than 20% of patients with chronic hepatitis C and HIV coinfection achieve a six months sustained virological response following treatment with interferon plus ribavirin (<LINK REF="REF-Olmelda-2003" TYPE="REFERENCE">Olmelda 2003</LINK>). Potential causes for the difference include the impaired immune response of patients with HIV and interactions with HIV antiretroviral therapy (<LINK REF="REF-Eyster-1994" TYPE="REFERENCE">Eyster 1994</LINK>; <LINK REF="REF-Soto-1997" TYPE="REFERENCE">Soto 1997)</LINK>. Considering the risk of serious adverse events, the low response rates made treatment of chronic hepatitis C among patients with HIV debatable. However, after the development of a pegylated form of interferon the treatment of chronic hepatitis C has been improved. A meta-analysis of randomised trials on peginterferon plus ribavirin found that about 50% of patients with chronic hepatitis C and no HIV achieved a six months sustained viral response (<LINK REF="REF-Simin-2007" TYPE="REFERENCE">Simin 2007</LINK>). Some randomised trials including patients with chronic hepatitis C and HIV found promising results after treatment with peginterferon plus ribavirin (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>). However, the sustained virological response varied from about 25% to 40% and the risk of adverse events including liver failure, lactic acidosis, and anaemia was higher for patients with HIV than for patients without HIV. We, therefore, performed a systematic review on antiviral treatment for patients with chronic hepatitis C and HIV coinfection.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio">
<P>To evaluate the beneficial and harmful effects of treatment for chronic hepatitis C in patients with HIV.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-09 22:11:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2009-10-29 13:20:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trials were included irrespective of language or publication status. Quasi-randomised trials and observational studies were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-07-15 16:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with chronic hepatitis C and stable HIV co-infection as defined by the authors of the individual trials. Patients were included irrespective of previous antiviral therapy, level of plasma HIV RNA, and CD4 positive cell counts.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-10-02 13:01:15 +0200" MODIFIED_BY="Alfonso Iorio">
<P>Randomised comparisons of peginterferon (any type, ie, alpha 2a or 2b) plus ribavirin versus peginterferon or interferon (any type, ie, alpha 2a or 2b) plus ribavirin and randomised comparisons of peginterferon plus ribavirin given for different doses or treatment durations were included. The treatment duration had to be at least 12 weeks. All other antiviral treatments against hepatitis C were also considered including interferon, pegylated interferon, ribavirin, and amantadine versus placebo or no interventions, or different regimens of antiviral therapy. Treatments could have been administered as a combination or monotherapy. Any type of antiretroviral treatment and cotrimoxazole prophylaxis for HIV-associated opportunistic infections were allowed if provided to all patients, irrespective of randomisation group.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-10-29 13:20:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-10-29 13:20:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>1. Virologic response defined as loss of hepatitis C virus RNA</P>
<UL>
<LI>at the end of treatment</LI>
<LI>at least six months after treatment (sustained virological response).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>2. Mortality.<BR/>3. Progression to acquired immunodeficiency syndrome (AIDS) related illness.<BR/>4. Hospitalisation.<BR/>5. Histological response.<BR/>6. Biochemical response (normalisation of transaminases).<BR/>7. Level of CD4-positive T-Lymphocytes.<BR/>8. Level of HIV RNA.<BR/>9. All adverse events defined as any untoward medical occurrence, sign, symptom, or disease.<BR/>10. Withdrawals and dropouts.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-09 13:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible trials were identified through electronic and manual searches and correspondence with experts. The electronic searches in <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(<LINK REF="REF-Gluud-2009" TYPE="REFERENCE">Gluud 2009</LINK>), the <I>Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>)<I> </I>in <I>The Cochrane Library</I>, <I>MEDLINE</I>, <I>EMBASE, </I>and<I> Science Citation Index Expanded </I>(<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>)<I> </I>were performed from date of inception to end of May 2009 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). The manual searches included scanning of reference lists in relevant papers on hepatitis C and HIV, specialist journals, conference proceedings, and the registers of ongoing clinical trials available through controlled-trials.com (including ClinicalTrials.gov and UK Clinical Trials Gateway).</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-09 22:11:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We conducted the review according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and <I>The</I> <I>Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2009" TYPE="REFERENCE">Gluud 2009</LINK>).</P>
<P>Two authors (AI and LLG) performed the searches and listed all trials that were eligible for inclusion. All authors evaluated whether the trials fulfilled the inclusion criteria. Excluded trials were listed with the reason for exclusion. All authors independently extracted data using standardised extraction forms. Disagreements were resolved by discussion.</P>
<P>From each trial data were gathered on included patients (inclusion criteria, previous antiviral therapy, mean age, proportion of men, proportion with hepatitis C virus genotype 1, and proportion with cirrhosis), treatments (dose and duration), and trials (bias risk, country of origin, number of clinical sites, funding, and publication status).<BR/>
</P>
<QUALITY_ASSESSMENT MODIFIED="2009-10-02 13:01:20 +0200" MODIFIED_BY="Alfonso Iorio">
<P>Due to the risk of overestimation of beneficial intervention effects in randomised trials with a high risk of bias (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), we independently assessed the risk of bias of the trials. We filled in the risk-of-bias tables as indicated in the <I>Cochrane Handbook for Systematic Reviews and Interventions </I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and <I>The Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2009" TYPE="REFERENCE">Gluud 2009</LINK>).</P>
<P>Methodological quality was defined as the control of bias in the treatment comparisons. Randomisation (allocation sequence generation and allocation concealment) and blinding were extracted as measures of bias control (<LINK REF="REF-Gluud-2006" TYPE="REFERENCE">Gluud 2006</LINK>). The allocation sequence generation was classified as adequate if based on a table of random numbers, computer generated random numbers, or similar. The allocation concealment was described as adequate if patients were randomised through a central independent unit or using serially numbered opaque sealed envelopes, coded identically appearing drug bottles, or similar. Blinding was described as adequate if the trial was described as double blind and both patients and investigators were unaware of the allocated treatment by use of identically appearing active treatments or placebo. We also extracted data on whether outcome assessors were blinded and whether the effect of blinding was assessed. To assess the risk of bias further we also extracted the number and reasons for dropouts and withdrawals, whether a sample size calculation was reported, and whether the planned sample size was achieved. The primary outcome measure defined in the individual trials was extracted to estimated the risk of outcome reporting bias.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-10-29 13:44:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>All analyses were performed in Review Manager 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>), except Chi<SUP>2</SUP> statistic to reassess results from studies not included in pooled analysis, which were performed with Stata 9.2, StataCorp College Station, TX, USA. Chi<SUP>2</SUP> statistic related probability was calculated following Pearson for large tables and following Fisher's exact test for tables with any of cell &#8804; 5. The primary meta-analyses were performed using fixed-effect models. The results were presented as risk ratio (RR) with 95% confidence intervals (CI). Intertrial heterogeneity was estimated through random-effects meta-analyses and through calculation of Chi<SUP>2</SUP> statistic. The results of random-effects meta-analyses are reported in case of considerable intertrial heterogeneity (Chi<SUP>2</SUP> statistic &lt; 0.1). Data on all patients randomised were included based on the intention-to-treat principle, irrespective of compliance or follow-up. To manage missing data, we used a worst case scenario analysis and, since we had a positive outcome (virological response), all missing data were counted as non-responder. Due to the large number of patients without a post treatment liver biopsy, sensitivity analyses were performed with inclusion of patients with paired pre- and post-treatment biopsies. Subgroup analyses on the sustained virological response of patients with genotype 1 or 4 and patients with genotypes 2 and 3 were performed. No data on continuous outcome measures were available for analyses. Due to the limited number of trials, no meta-regression or funnel plot regression analyses were performed. Since all trials were published as full paper articles, no additional analyses on publication bias was performed.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-11-11 16:15:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2009-11-09 22:13:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SEARCH_RESULTS MODIFIED="2009-09-23 08:09:42 +0200" MODIFIED_BY="Alfonso Iorio">
<P>The number of references identified through the electronic searches was 216. After reading the titles and abstracts, 79 potentially relevant references were retrieved for further assessment. After excluding reviews, observational studies, and trials on patients without hepatitis C or HIV, we identified 14 randomised trials on patients with chronic hepatitis C and HIV (<LINK REF="STD-Sax-2001" TYPE="STUDY">Sax 2001</LINK>; <LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>; <LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>; <LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>; <LINK REF="STD-Puoti-2004" TYPE="STUDY">Puoti 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>; <LINK REF="STD-ICOS-2005" TYPE="STUDY">ICOS 2005</LINK>; <LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>; <LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>; <LINK REF="STD-Laguno-2009" TYPE="STUDY">Laguno 2009</LINK>). Eight additional ongoing randomised trials were identified through the manual searches. The total number of references to the included trials (identified through the manual and electronic searches) was 42 (range 1 to 10). All trials were described in at least one full paper publication and were performed in USA or Europe.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-11-09 22:13:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>All trials included patients with chronic hepatitis C and stable HIV. The diagnosis of chronic hepatitis C was based on presence of hepatitis C virus RNA in the blood, persistently elevated plasma transaminases for at least six months, and a pre-treatment liver biopsy showing evidence of chronic viral hepatitis. The HIV infection was confirmed by detection of anti-HIV antibodies or RNA in serum. The definition of stable HIV infection included assessment of CD4 positive lymphocyte counts and HIV RNA levels and no or stable antiretroviral therapy during at least three months before the randomisation in the hepatitis C trial. Exclusion criteria were very similar in all the trials and consisted of decompensated liver disease, autoimmune hepatitis, chronic hepatitis B, significant co-morbidities, ongoing alcohol or drug abuse, or pregnancy. Patients with HIV-related opportunistic infections were also excluded. Accordingly, the initial evaluation of patients included screening for hepatitis B, autoimmune liver disease, hepatocellular carcinoma, decompensated liver disease (with ascites, encephalopathy, or oesophageal varices), and other concurrent illnesses including infections, kidney disease, cardiovascular disease, psychiatric illnesses, poorly controlled diabetes, seizures, or haematological diseases with anaemia, low platelets, or neutropenia.</P>
<P>The mean age of included patients was reported in all trials and ranged from 36 to 45 years. Most patients were men (proportion of men ranged from 60% to 90%). The mean proportion of patients with hepatitis C genotype 1 ranged from 44% to 78%. The proportion of patients with cirrhosis ranged from 7% to 45%.</P>
<P>In eight trials comparing peginterferon plus ribavirin versus interferon plus ribavirin or peginterferon alone, or different molecules of peginterferon, the dose of peginterferon was 180 microgram (alfa-2a) or 1.5 microgram/kg (alfa-2b) once weekly (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>; <LINK REF="STD-ICOS-2005" TYPE="STUDY">ICOS 2005</LINK>; <LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>; <LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>; <LINK REF="STD-Laguno-2009" TYPE="STUDY">Laguno 2009</LINK>). In one of these trials (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>), the daily dose of ribavirin was increased gradually from 600 mg to 1000 mg. The remaining trials assessed a dose of 800 mg administered in two doses. In the trial that compared two different treatment durations (<LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>), the dose of peginterferon was 100 microgram or 150 microgram once weekly and the dose of ribavirin 800 mg to 1200 mg daily, both adjusted according to body weight. The dose of interferon was 6 million unit three times weekly for 12 weeks then 3 million units three times weekly in one trial (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>) and 3 million units three times weekly in the remaining four trials that included a treatment group receiving interferon plus ribavirin. In one trial, patients were randomised to 24 or 48 weeks of treatment (<LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>). In three trials (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>), patients were treated for 24 weeks if infected with hepatitis C genotype 2 or 3 or if a virological or histological response was seen. The remaining patients were treated for 48 weeks.</P>
<P>Six trials evaluated treatment regimens different from peginterferon (<LINK REF="STD-Sax-2001" TYPE="STUDY">Sax 2001</LINK>; <LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>; <LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>; <LINK REF="STD-Puoti-2004" TYPE="STUDY">Puoti 2004</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>). Five trials included patients who were not previously treated for chronic hepatitis C (treatment naive). In one trial, patients had not received treatment for hepatitis C during the last six months before entering the trial (<LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>). The trials compared high versus low dose interferon plus ribavirin (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>), interferon plus ribavirin versus no treatment (<LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>), high dose interferon plus ribavirin and amantadine versus standard dose interferon and ribavirin (<LINK REF="STD-Sax-2001" TYPE="STUDY">Sax 2001</LINK>; <LINK REF="STD-Puoti-2004" TYPE="STUDY">Puoti 2004</LINK>). In most trials, the standard dose of interferon was 3 MU administered three times weekly. In the trials assessing different doses of interferon, daily injection with 5 MU or 6 MU were assessed.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-11-09 14:01:17 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies were excluded (<LINK REF="STD-Makris-1991" TYPE="STUDY">Makris 1991</LINK>; <LINK REF="STD-Brau-2004" TYPE="STUDY">Brau 2004</LINK>; <LINK REF="STD-Khalili-2005" TYPE="STUDY">Khalili 2005</LINK>; <LINK REF="STD-Coral-2007" TYPE="STUDY">Coral 2007</LINK>). Details are provided in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-11 16:12:38 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for overall risk of bias assessment. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for bias assessment in individual studies. In the following paragraphs a summary risk of bias assessment is given for every comparison within the review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Peginterferon plus ribavirin versus interferon plus ribavirin</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation and allocation concealment  </HEADING>
<P>Treatment allocation sequence generation and concealment of treatment allocation were adequate in four out of five trials (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>; <LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>). One trial (<LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>) reported adequate allocation sequence generation, but did not describe how the allocation was concealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding  </HEADING>
<P>None of the trials blinded the comparison between peginterferon and interferon. One trial reported adequate assessor blinding to the treatment assignments (<LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>) regarding virological and histological outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data  </HEADING>
<P>All the trials had a list of withdrawals. All trials provided a clear description of losses to follow-up including reasons for dropouts and withdrawals. Furthermore, attempts were made to secure follow-up data on patients who were withdrawn from treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting  </HEADING>
<P>All trials specified that the primary outcome measure was sustained virological response and reported this analysis. Only two trials reported the histological response of patients in relation to the allocated treatment group (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Peginterferon plus ribavirin versus peginterferon</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation and allocation concealment  </HEADING>
<P>Treatment allocation sequence generation and concealment of treatment allocation was adequate in one out of two trials (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>). The other trial (<LINK REF="STD-ICOS-2005" TYPE="STUDY">ICOS 2005</LINK>) reported adequate allocation concealment, but did not describe how the allocation sequence was generated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding  </HEADING>
<P>One trial reported adequate double blinding (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>) using an identical ribavirin placebo. Both sponsors, investigators, and patients were kept blinded regarding the allocation to ribavirin or placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data  </HEADING>
<P>The two trials had a list of withdrawals and provided a clear description of losses to follow-up including reasons for dropouts and withdrawals. Furthermore, attempts were made to secure follow-up data on patients who were withdrawn from treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting  </HEADING>
<P>The two trials specified that the primary outcome measure was sustained virological response and reported this analysis. Only one trial reported the histological response of patients in relation to the allocated treatment group (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">High-dose versus low-dose interferon plus ribavirin</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation and allocation concealment  </HEADING>
<P>One of three trials (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>) reported adequate allocation concealment, but none of the trials described how the allocation sequence was generated (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding  </HEADING>
<P>None of the trials blinded the comparison between high-dose versus low-dose interferon.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data  </HEADING>
<P>All the trials had a list of withdrawals. All trials provided a clear description of losses to follow-up including reasons for dropouts and withdrawals. Furthermore, attempts were made to secure follow-up data on patients who were withdrawn from treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting  </HEADING>
<P>All trials specified that the primary outcome measure was sustained virological response and reported this analysis. One trial reported the histological response of patients in relation to the allocated treatment group (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-11 16:15:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The predefined primary outcome of this review is virological response, ie, virus clearance from plasma, which is the primary outcome of many of the included trials and of other Cochrane reviews and protocols investigating antiviral treatment for HCV infection. We also investigated as secondary outcomes some 'hard' outcomes, namely mortality, progression of liver disease (histological and biochemical response), and progression to AIDS. To stress the clinical importance of these hard outcome measures, we decided to start the results section with a brief description of the overall results about mortality and disease progression.</P>
<P>The total all-cause mortality in all trials was 23 out of 2111 patients (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The allocated treatment group was not reported for two of these patients. The cause of death was liver failure for 10 patients. Two of these patients were randomised to peginterferon plus ribavirin and two were randomised to interferon plus ribavirin. The allocated treatment group was not reported for the remaining patients. Other causes of death included suicide, lactic acidosis, heart disease, and cancer.</P>
<P>It was not possible to evaluate the number of patients with progression to AIDS, neither the effect of anti-HCV treatment on HIV related outcome measures due to paucity and variability of data reported. The same applied to biochemical markers of liver disease. Histology was reported for a minority of the trials and patients, and included in the relevant comparison (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Peginterferon plus ribavirin versus interferon plus ribavirin</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Virologic response defined as loss of hepatitis C virus RNA from the blood</HEADING>
<P>Two hundred forty six of patients out of 673 randomised to peginterferon plus ribavirin achieved a sustained virological response (37%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). One hundred eight out of 667 patients randomised to interferon plus ribavirin had a sustained virological response (27%). Fixed-effect meta-analysis model found that peginterferon plus ribavirin increased the risk of achieving a sustained virological response (RR 2.25, 95% CI 1.84 to 2.75; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The intertrial heterogeneity was considerable (P = 0.01) with the risk ratio of achieving a sustained virological response ranging from RR 1.38 (95% CI 0.97 to 1.96) to RR 3.40 (95% CI 2.41 to 4.80). However, the benefit of peginterferon was still found when a random-effects model was used (RR 2.16, 95% CI 1.47 to 3.18).</P>
<P>At the end of treatment with peginterferon plus ribavirin, 44% (298 of 673 patients) were virological responders (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Among patients treated with interferon plus ribavirin, the proportion with an end of treatment virological response was 19% (129 of 667 patients). Overall, the benefit of peginterferon plus ribavirin was statistically significant in both fixed-effect and random-effects meta-analyses (RR 2.28, 95% CI 1.91 to 2.72 and RR 2.14, 95% CI 1.46 to 3.13, respectively; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). However, there was considerable intertrial heterogeneity (P = 0.0002).</P>
<P>In subgroup analyses, data on the virological response were gathered separately for patients infected with hepatitis C virus genotype 1 or 4 and patients with genotype 2 or 3. The proportion of patients with a sustained virological response after treatment with peginterferon plus ribavirin (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), was 26% (109 of 423 patients) for patients with genotype 1 or 4 and 56% of patients with genotype 2 or 3 (130 of 230 patients). Among patients randomised to interferon plus ribavirin, the proportion with a sustained virological response was 32 of 419 (8%) for patients with genotype 1 or 4 and 72 of 216 (33%) for genotype 2 or 3. Peginterferon plus interferon increased the risk of achieving a sustained virological response for both subgroups (genotype 1 or 4 RR 3.36, 95% CI 2.33 to 4.86 and genotype 2 or 3 RR 1.70, 95% CI 1.36 to 2.12). At the end of treatment with peginterferon, the proportion with a virological response was 35% (147 of 423) for patients with genotype 1 or 4 and 62% (142 of 230) for patients with genotype 2 or 3 (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). For patients infected with genotype 1 or 4, the proportion of patients with a virological response was significantly higher at the end of treatment with peginterferon plus ribavirin versus interferon plus ribavirin (RR 3.92, 95% CI 2.82 to 5.47). There was little intertrial heterogeneity (P = 0.27). For patients with genotype 2 or 3, no significant difference in the end of treatment virological response was detected (RR 1.16, 95% CI 0.99 to 1.36).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>No significant difference was found between patients randomised to peginterferon plus ribavirin versus interferon plus ribavirin (RR 1.27, 95% CI 0.49 to 3.30; Chi<SUP>2</SUP> statistic = 0.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>The most frequent adverse events were anaemia, flu-like symptoms, and depression (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Fourteen per cent of patients randomised to peginterferon plus ribavirin developed anaemia and 64% flu-like symptoms. Both anaemia and flu-like symptoms occurred significantly more frequently among patients randomised to peginterferon plus ribavirin (RR 1.57, 95% CI 1.16 to 2.14 and RR 1.16, 95% CI 1.07 to 1.26, respectively). The risk of depression was not significantly different in the two treatment groups (RR 0.97, 95% 0.80 to 1.17).</P>
<P>Several patients with lactic acidosis and hepatic decompensation were reported, but the reported data did not allow meta-analyses. The severity ranged from life threatening to mild. Severe hepatic decompensation mainly occurred for patients with histological cirrhosis at randomisation. None of the trials reported a clear association between the concomitant antiretroviral treatment and adverse events.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals and dropouts</HEADING>
<P>All trials reported the number of losses to follow-up (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). The proportion of patients who dropped out or were withdrawn for any reason was significantly lower among patients randomised to peginterferon plus ribavirin compared with interferon plus ribavirin (30% and 36%; RR 0.82, 95% CI 0.71 to 0.96). The risk of adverse events did not readily explain this difference.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other secondary outcome measures</HEADING>
<P>No data were available allowing analysis of the outcomes progression to AIDS, hospitalisation, biochemical response, level of CD4-positive lymphocytes, or levels of HIV RNA. One trial reported the histological response in relation to treatment group for virological responders, but not for patients without a virological response (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>). Two trials reported the proportion of patients with a histological improvement in liver biopsies taken before and after treatment (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>). The number of patients with paired biopsies was 235 of 495 patients randomised to peginterferon plus ribavirin and 239 of 496 patients randomised to interferon plus ribavirin in the two trials (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The proportion with improved histology was highest among patients in the peginterferon plus ribavirin group irrespective of whether intention to treat or per protocol analyses were performed (RR 2.42, 95% CI 1.72 to 3.40 and RR 2.44, 95% CI 1.78 to 3.34, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis</HEADING>
<P>We performed a sensitivity analysis to investigate the source of heterogeneity for HCV virological response (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), and we found it potentially related to the use of peginterferon 2a (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>) or peginterferon 2b (<LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>; <LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>). In all the trials, the control group was interferon, and both active and control group were treated with ribavirin. Sustained virological response was higher for peginterferon 2a than for peginterferon 2b (RR 3.19, 95% CI 2.33 to 4.37 compared to RR 1.69, 95% CI 1.30 to 2.19. Similar results were found for end of treatment virological response (RR 3.36, 95% CI 2.53 to 4.48 and RR 1.62, 95% CI 1.30 to 2.02. Since peginterferon 2a was used mainly in USA and peginterferon 2b in Europe, where a higher percentage of patients is infected with genotype 2-3 HCV and presents liver cirrhosis, we also evaluated the virological response for peginterferon 2a and 2b by genotype. For genotype 2 and 3 peginterferon 2a showed a RR for sustained virological response of 2.89 (95% C.I. 1.96 to 4.25) and peginterferon 2b 1.14 (95% C.I. 0.87 to 1.51). For genotype 1 and 4 peginterferon 2a showed a RR for sustained virological response of 3.79 (95% C.I. 2.21 to 6.48) and peginterferon 2b 2.98 (95% C.I. 1.80 to 4.95).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Peginterferon plus ribavirin versus peginterferon alone</I>
</HEADING>
<P>Two trials compared peginterferon with or without ribavirin (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-ICOS-2005" TYPE="STUDY">ICOS 2005</LINK>). Both trials reported the virological response, losses to follow-up, and adverse events. One trial reported mortality and histology (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Virologic response defined as loss of hepatitis C virus RNA from the blood</HEADING>
<P>The proportion of patients with a sustained virological response (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) was highest among patients randomised to peginterferon plus ribavirin (131 of 359), versus peginterferon alone (64 of 355, RR 2.03, 95% CI 1.57 to 2.63). The difference was seen for patients with genotype 1 or 4 (RR 1.71, 95% CI 1.24 to 2.38) as well as patients with genotype 2 or 3 (RR 1.26, 95% CI 1.00 to 1.58). Likewise, the proportion of patients with an end of treatment virological response was higher for patients randomised to peginterferon plus ribavirin than for patients randomised to peginterferon (156 of 359 (43%) versus 101 of 355 (28%); RR 1.53, 95% CI 1.25 to 1.87; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>. The difference was found for patients with genotype 1 or 4 as well as patients with genotype 2 or 3 (RR 2.01, 95% CI 1.33 to 3.05 and RR 1.91, 95% CI 1.40 to 2.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Five deaths were reported in the two treatment groups (RR 1.00, 95% CI 0.29 to 3.41; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Histological response</HEADING>
<P>The number of patients with improved histology and paired liver biopsies was 77 of 135 (57%) in the peginterferon plus ribavirin group and 52 of 134 (39%) in the peginterferon group. The number of patients with improved histology was highest in the peginterferon plus ribavirin group, irrespective of whether only patients with paired biopsies (RR 1.48, 95% CI 1.08 to 2.02) or all patients were included (RR 1.47, 95% CI 1.14 to 1.90).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events, withdrawals, and dropouts</HEADING>
<P>In total, 113 patients randomised to peginterferon plus ribavirin and 129 patients randomised to peginterferon were lost to follow-up (RR 0.86, 95% CI 0.71 to 1.05; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Six patients in both treatments groups became anaemic (RR 1.00, 95% CI 0.33 to 3.05; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). No significant differences were seen in occurrence of flu-like symptoms (RR 2.40, 95% CI 0.35 to 16.58) or depression (RR 0.76, 95% CI 0.57 to 1.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other secondary outcome measures</HEADING>
<P>No data were available for any of the remaining outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">High-dose interferon plus ribavirin versus low-dose interferon plus ribavirin</HEADING>
<P>Three trials compared treatment regimens with high-dose versus standard doses of interferon plus ribavirin (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>). All trials included naive patients. The treatment regimens assessed varied considerably both in the high- and low-dose regimens.</P>
<P>High-dose regimens were Interferon 9 million unit daily for 2 weeks, then 3 million unit daily for 22 weeks, then 3 million unit 3 times for a total of 48 weeks (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>); interferon 5 million unit daily for 6 weeks, then 3 million unit for a total of six months (<LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>), interferon 3 million unit daily for a total of 48 weeks (<LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>).</P>
<P>Low dose regimens were interferon 6 million unit 3 times weekly for 24 weeks, then 3 million unit three times weekly for 24 weeks (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>), interferon 3 million unit three times weekly for six months (<LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>) or 48 weeks (<LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Virologic response defined as loss of hepatitis C virus RNA from the blood</HEADING>
<P>All the trials were relatively small and none found a significant difference in virological response when analysed separately (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> ). When the results of the trials were combined, the high dose interferon regimens did not significantly increase the proportion of patients with a six months sustained virological response (16% versus 11%, RR 1.47, 95% 0.87 to 2.49). The results of the individual trials varied with end of treatment virological response (24% versus 16%, RR 1.54, 95% CI 1.00 to 2.37). It was not possible to analyse the data by genotype.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Two trials reported that no patients died during follow-up (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals and dropouts</HEADING>
<P>Two trials reported the number of losses to follow-up (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>). No significant difference was found among treatment groups (14% and 12%; RR 1.31, 95% CI 0.70 to 2.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>One trial reported the number of adverse events combined for the two treatment groups (<LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>). In one trial (<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>), none of 37 patients in the high dose interferon and three of 31 patients in the control group developed anaemia (RR 0.12, 95% CI 0.01 to 2.24). One trial reported the number of patients with haematological adverse events, but did not specify the number with anaemia (<LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>). No significant difference was found for the risk of flu-like symptoms (2% versus 4%, RR 0.57, 91% CI 0.15 to 2.13) or depression (3% versus 3%, RR 0.90, 95% CI 0.36 to 2.23; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other treatments and regimens comparisons</HEADING>
<P>In the following, we describe the results of trials eligible for this review, for which it was not possible to perform a meta-analysis as only one trial evaluated the specific comparison or the studies were not enough similar to be meta-analysed.</P>
<P>
<B>Peginterferon plus ribavirin for 24 versus 48 weeks</B>
</P>
<P>One trial compared 24 versus 48 weeks of treatment with peginterferon plus ribavirin (<LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>). The trial reported the sustained virological response, which was seen for one of 16 patients randomised to 48 weeks and none of 11 patients randomised to 24 weeks of treatment (Fisher's exact P = 1.00). We were unable to analyse any of the remaining outcome measures for this trial. The losses to follow-up were 68%.</P>
<P>
<B>Peginterferon alpha-2a versus peginterferon alpha-2b</B>
</P>
<P>One trial compared 48 weeks of treatment with peginterferon alpha-2a versus peginterferon alpha-2b (<LINK REF="STD-Laguno-2009" TYPE="STUDY">Laguno 2009</LINK>). The trial reported the sustained virological response, which was seen for 44/96 (46%) of patients randomised to peginterferon alpha-2a and 36/86 (42%) patients randomised to peginterferon alpha-2b (Chi<SUP>2</SUP> statistic = 0.29, P = 0.59). Similar results were found for early virological response (59/86 and 77/96, Chi<SUP>2</SUP> statistic = 3.23, P = 0.07) . Adverse events were 12/96 in the peginterferon alpha-2a group and 7/86 in the peginterferon alpha-2b group (Chi<SUP>2</SUP> statistic = 0.92, P = 0.34). Similar data were found in the indirect comparison provided in <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> and <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
<P>
<B>Interferon plus ribavirin plus amantadine versus interferon plus ribavirin</B>
</P>
<P>One trial compared interferon 3 MU plus ribavirin plus amantadine 200 mg daily versus interferon 3 MU plus ribavirin (<LINK REF="STD-Puoti-2004" TYPE="STUDY">Puoti 2004</LINK>). The treatment duration ranged from 24 to 48 weeks depending on the genotype. In 80 patients, the following outcomes were described: sustained virological response (5/39 versus 9/41 with and without amantadine, respectively (Fisher's exact P = 0.38), end of treatment (12/39 versus 13/41 with and without amantadine, respectively (P = 0.93). Another trial evaluated the effect of interferon plus/minus amantadine in 7 patients and reported the following outcome: sustained virological response (0/3 patients and 1/4 patients with and without amantadine, respectively (Fisher's exact P = 1.00), end of treatment virological response (0/3 patients and 1/4 patients with and without amantadine, respectively (Fisher's exact P = 1.00)), mortality (0/3 patients and 0/4 patients with and without amantadine, respectively) (<LINK REF="STD-Sax-2001" TYPE="STUDY">Sax 2001</LINK>).</P>
<P>
<B>Interferon plus ribavirin versus no treatment</B>
</P>
<P>One trial compared interferon plus ribavirin versus no treatment (<LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>). Included patients were treatment naive or had not received treatment for their hepatitis C during at least six months before entering the trial. In the randomised comparison, patients were treated for only three months. The trial did not report sustained virological response, mortality, or the number of patients with anaemia or depression. Seven of 18 patients (40%) in the treatment group and none of 12 patients in the control group had an end of treatment virological response. The difference was statistically significant (Fisher's exact P = 0.02). Two patients in the treatment group and no patients in the control group dropped out of the trial (Fisher's exact P = 0.50). Both patients had adverse events. Fifteen patients in the treatment group and none of the patients in the control group developed flu-like symptoms (Fisher's exact P &lt; 0.01).<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-10 13:00:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2009-11-06 15:05:37 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The present review suggests that among patients with stable HIV, the treatment of concomitant chronic hepatitis C with peginterferon plus ribavirin is more effective than interferon plus ribavirin or peginterferon alone in achieving a virological or histological response. The overall sustained virological response of previously untreated patients was 37% after treatment with peginterferon plus ribavirin. However, although the included trials had nearly identical patient inclusion criteria, there was considerable intertrial heterogeneity. The sustained response in the individual trials ranged from 27% (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>) to 55% (<LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>). We also found that there were no noticeable differences between treatments regarding mortality. The number of losses to follow-up and the risk of adverse events were considerable in all treatment groups. About 30% of patients randomised to peginterferon plus ribavirin dropped out or were withdrawn from treatment compared with 36% of patients randomised to interferon plus ribavirin. The difference was not clearly related to the risk of adverse events. Several serious, in some patients fatal, adverse events occurred including hepatic decompensation, lactic acidosis, pancreatitis, and depression leading to suicide. One of the most frequent adverse events was anaemia, which was treated with a reduction in the dose of ribavirin, transfusion, or erythropoietin. The risk of anaemia and the risk of depression was highest during treatment with peginterferon plus ribavirin.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-11-09 22:36:41 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>As far as the genotype is concerned, it has to be noted that in one trial, treatment was stopped after 24 weeks when patients did not have virological or histological response (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>). In the remaining trials, all patients with genotype 1 or 4 were treated for 48 weeks. The subgroup analyses of this patient group found negligible intertrial heterogeneity. In comparison, patients with genotype 2 or 3 were treated for 24 to 48 weeks in some of the trials, depending on the virological response. The subgroup analyses of these patients showed considerable differences between the trials. One of the included trials compared the effect of treating patients for 24 or 48 weeks (<LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>). The trial found little difference in the sustained virological response rates of the two treatment regimens. However, the sample size of the trial was too small to make definite conclusions.</P>
<P>For patients without HIV, the recommended treatment for chronic hepatitis C is peginterferon 180 microgram or 1.5. microgram/kg once weekly plus ribavirin (<LINK REF="REF-Dienstag-2006" TYPE="REFERENCE">Dienstag 2006</LINK>). A large randomised trial found that the optimal dose of ribavirin for patients with hepatitis C genotype 1 is 1200 to 1000 mg daily depending on weight, and the optimal duration of therapy is 48 weeks (<LINK REF="REF-Hadziyannis-2006" TYPE="REFERENCE">Hadziyannis 2006</LINK>). For patients with genotype 2 or 3, the dose of ribavirin may be lowered to 800 mg daily and the duration of therapy to 24 weeks. In the present review, trials mainly assessed peginterferon at a dose of 180 microgram or 1.5 microgram/kg once weekly plus ribavirin 800 mg daily, irrespective of genotype. The sustained virological response in the trial using ribavirin 1000 mg to 1200 mg daily was 44% (<LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>) compared with 40% to 55% in trials using a lower dose of 800 mg to all patients (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>). In absence of a clear demonstration of superiority of a specific ribavirin dosage, and until new evidence will be available, these findings might support recommendations (<LINK REF="REF-EACS-guidelines" TYPE="REFERENCE">EACS guidelines</LINK>) that, for patients with HIV, the choice of the 800 mg dose of ribavirin may be warranted to lower the occurrence of adverse events.</P>
<P>Regarding treatment duration, the highest sustained responses were seen in a trial assessing 48 weeks of treatment, irrespective of genotype (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>). However, only one randomised head-to-head comparison of different durations of treatment was found (<LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>), and no definitive conclusion may be drawn regarding this issue.</P>
<P>Regarding the type of interferon, the association found between treatment effect and peginterferon 2a or 2b should be cautiously interpreted because of the indirect nature of the comparison. Furtermore peginterferon 2a was used mainly in USA and peginterferon 2b in Europe, where a higher percentage of patients is infected with genotype 2-3 HCV and presents liver cirrhosis. We tried to adjust our findings by performing a separate analysis for genotypes 1-4 and 2-3, which confirmed the difference of sustained virological response for the two molecules, but we were not able to incorporate in the analysis the different severity of the disease at baseline. A head-to-head, open label, randomised, likely underpowered comparison found a similar SVR rate in patients treated with peginterferon 2a versus 2b (<LINK REF="STD-Laguno-2009" TYPE="STUDY">Laguno 2009</LINK>).</P>
<P>Trials in which patients were treated for 24 weeks if a virological or histological response was seen, if patients were infected with genotype 2 or 3 or had a low viral load, achieved lower virological responses (<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>). For patients without HIV, peginterferon monotherapy may be considered for patients with contraindications to ribavirin (<LINK REF="REF-VA-guidelines" TYPE="REFERENCE">VA guidelines</LINK>). In the present review, we found that the proportion of patients infected with genotype 1 or 4 who achieved sustained virological response was 13% after treatment with peginterferon alone. This response may not be considered satisfactory considering the risk of adverse events. For patients with genotype 2 or 3, the proportion of patients with a sustained viral response after peginterferon was 29%. Accordingly, peginterferon monotherapy may be considered in this patient group.</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2009-11-10 13:00:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The main limitation of the present review was that the ultimate objective of treating patients with hepatitis C, whether or not they are co-infected with HIV, is to prevent (or at least reduce the probability of developing) the ravages (including death) of end-stage liver disease, namely decompensated cirrhosis, hepatocellular carcinoma, and/or liver transplantation. There is currently scarce evidence from randomised trials that treatment with antiviral agents accomplishes this deed. On the other hand, it is usually considered appropriate to focus on a surrogate outcome (like sustained virological response, ie, HCV-RNA clearance from the blood) if it were a validated one. While patients who have sustained virological response do usually seem to have better long-term courses than do those who do not have them after treatment (or non-randomised controls), this observation must be tempered with the knowledge that only a small percentage of HCV-infected individuals develop end-stage problems (and this is probably true for the coinfected group as well) and that predictors of sustained virological response are ones that are also predictors for a benign long-term outcome. Furthermore, we now know that a few patients with sustained virological response are still developing liver complications. Finally, and perhaps most importantly, the completed HALT-C trial (<LINK REF="REF-Di-Bisceglie-2008" TYPE="REFERENCE">Di Bisceglie 2008</LINK>) found that the long-term course of patients with severe fibrosis previously non-responder to antiviral treatment who were treated for years with pegylated interferon did no better than the ones who were not treated. On the other hand, the treated group did have significant improvements in sustained virological response. This suggests that there is a disconnect between the sustained virological response and clinical outcomes, so sustained virological response may not be a valid surrogate outcome to use in clinical trials.</P>
<P>Another important limitation is that most of the available evidence comes from head-to-head comparisons between different treatment regimens, and there were no trials comparing peginterferon with no treatment or placebo. However, peginterferon was found to be superior to interferon, which was previously validated against placebo.</P>
<P>Thus, the decision to use or not antiviral treatment has to be taken by balancing the adverse event risks it produces against the indirect demonstration of its efficacy obtained with the use of unvalidated outcome measure.</P>
<P>Another limitation lays in the limited number of trials, which meant that we were unable to analyse reasons for intertrial heterogeneity. In particular we did not have individual patient data nor enough trials to analyse in a meta-regression model the effect of variables like race, sex, age, weight, insuline resistance, HCV and HIV viral load, duration of undetectable HCV plasma levels, which all were found to affect the proportion of patients who achieve sustained virological response. Our subgroup analyses suggest that the differences between trials may be related to the HCV genotype, the duration of treatment, or the type of peginterferon, ie, 2a or 2b.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-11-09 22:39:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>There are conflicting results as to whether hepatitis C affects on the course of HIV infection. It was reported that hepatitis C had no effect on the progression of HIV or on the virological or immunological response to HAART (<LINK REF="REF-Rockstroh-2005" TYPE="REFERENCE">Rockstroh 2005</LINK>). Another study found that hepatitis C may influence the morbidity and mortality among patients with HIV through impaired CD4 cell recovery in patients receiving potent antiretroviral therapy (<LINK REF="REF-Greub-2000" TYPE="REFERENCE">Greub 2000</LINK>). </P>
<P>The evidence concerning the effect of HIV on the course of chronic hepatitis C is more clear. Patients with chronic hepatitis C have an increased risk of developing cirrhosis if they are co-infected with HIV (<LINK REF="REF-Benhamou-1999" TYPE="REFERENCE">Benhamou 1999</LINK>). In a large cohort study (<LINK REF="REF-Bica-2001" TYPE="REFERENCE">Bica 2001</LINK>), liver disease was the leading cause of death after the introduction of HAART. The duration of follow-up in the present review does not allow for any conclusions regarding the effect of treatment on clinical outcome measures. Our main conclusions are, therefore, based on the serological responses in the blood. Additional evidence is needed to determine whether the effect of peginterferon plus ribavirin on virological markers and histology result in decreased mortality and morbidity.</P>
<P>While we were performing our analysis, an industry-driven meta-analysis was published (<LINK REF="REF-Kim-2007" TYPE="REFERENCE">Kim 2007</LINK>). Compared to the analysis by <LINK REF="REF-Kim-2007" TYPE="REFERENCE">Kim 2007</LINK>, our present meta-analysis included seven more trials and considered additional comparison and outcomes (<LINK REF="STD-Sax-2001" TYPE="STUDY">Sax 2001</LINK>; <LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>; <LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>; <LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>; <LINK REF="STD-Puoti-2004" TYPE="STUDY">Puoti 2004</LINK>; <LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>; <LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>). However, as far as to the comparisons among peginterferon plus ribavirin versus peginterferon alone and peginterferon plus ribavirin versus interferon plus ribavirin, the results of the two meta-analyses are consistent.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-09 22:41:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2009-10-29 13:34:13 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Having clear in mind that a direct comparison against no treatment or placebo has not yet been performed and that mainly plasma virus clearance from the blood was considered in the available trials, peginterferon plus ribavirin may be considered the treatment of choice for chronic hepatitis C in patients with stable HIV. The evidence only supports treatment of patients who have not previously received antiviral therapy with interferon or ribavirin. The treatment should be monitored for adverse events including lactic acidosis, hepatic decompensation, depression, and anaemia, which globally account for 50% of the overall mortality (1% in 12 to 18 months) in this patient population.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-09 22:41:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>A long-term trial comparing the best treatment currently available, ie, peginterferon plus ribavirin, with no treatment at all, using hepatic morbidity and mortality (as well as all-cause mortality) as the primary outcomes is still lacking and worthy to be conducted, provided that ethical issues and quest for treatment does not preclude investigators and patients participation. Future trials should always use a stratification by HCV genotype. Additional randomised trials are necessary to assess the effect of peginterferon plus ribavirin in relation to the duration of therapy, especially in patients with hepatitis C genotype 2 or 3, and in relation to HIV status. Additional trials comparing peginterferon plus ribavirin versus interferon plus ribavirin or peginterferon alone do not seem warranted. The sample size should be clearly accounted for and calculated for the expected frequency of response; scientific societies should attempt to standardise treatment schemes and outcome measures (both time and outcome) to allow pooling of results. Finally, large phase IV trials would be necessary to assess the incidence of rare serious adverse events and the association between treatment and relevant clinical outcome measures, like overall mortality, liver-related mortality, liver-related morbidity, and progression to AIDS.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-02-17 18:11:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Thank you to Sarah Klingenberg and Dimitrinka Nikolova for helping us with performing the literature searches. Thanks to Ronald L Koretz, USA for relevant suggestions to improve the review and particularly the discussion of results. Thanks to the whole editorial group at Cochrane Hepato-Biliary Group group for advice and fruitful discussion.</P>
<P>Peer Reviewers: Kamal Kishore, Fiji Islands; Maribel Rodriguez-Torres, Spain; DP. Kotler, USA.<BR/>Contact Editor: Bodil Als-Nielsen.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None of the authors have potential conflicts of interest regarding the present review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-11-09 22:41:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>AI drafted the protocol and review. AI and LLG performed the searches. All authors participated in the data extraction and analyses, and in the revision of the review. All authors have approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-09-18 13:41:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We initially planned to analyse the predictive value of early virological treatment, but the outcome was finally dropped because none of the trials reported data available for a meta-regression analysis.</P>
<P>Following the conversion of our review to RevMan 5 format, we have also elaborated on the assessment of bias and included risk of bias tables. We added information on the risk of incomplete data assessment, reporting bias, and other apparent biases.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-09 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-11-09 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-11-09 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTG-2004" MODIFIED="2009-11-09 14:05:48 +0100" MODIFIED_BY="[Empty name]" NAME="ACTG 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-23 13:05:35 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, et al</AU>
<TI>Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1&#8211;coinfected subjects</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1375-83</PG>
<IDENTIFIERS MODIFIED="2008-07-10 00:08:40 +0200" MODIFIED_BY="Emanuela Marchesini"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-03 19:39:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackard JT, Kang M, St Clair JB, Lin W, Kamegaya Y, Sherman KE, et al</AU>
<TI>Viral factors associated with cytokine expression during HCV/HIV co-infection</TI>
<SO>Journal of Interferon and Cytochine Research</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>263-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:14:22 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chung R, Andersen J, Alston B, Vallee M, Robbins G, Nevin T, et al</AU>
<TI>A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071</TI>
<SO>9th Conference on Retroviruses and Opportunistic Infections (CROI)</SO>
<YR>2002</YR>
<PG>LB15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-18 13:25:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chung R, Andersen J, Volberding P, Robbins R, Liu T, Sherman K, et al</AU>
<TI>A randomized, controlled trial of peg-interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons: follow-up results of ACTG A5071</TI>
<SO>The 11th Conference on Retroviruses and Opportunistic Infections</SO>
<YR>2004</YR>
<PG>110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:16:44 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<PG>451-9</PG>
<IDENTIFIERS MODIFIED="2008-09-23 13:16:44 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<IDENTIFIER MODIFIED="2008-09-23 13:16:44 +0200" MODIFIED_BY="Sarah Louise Klingenberg" TYPE="OTHER" VALUE="ClinicalTrials.gov NCT00008463"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-18 13:31:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al</AU>
<TI>Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection</TI>
<SO>AIDS</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>767-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al</AU>
<TI>Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection</TI>
<SO>AIDS</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>345-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-09 14:05:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwarze-Zander C, Blackard JT, Zheng H, Addo MM, Lin W, Robbins GK, et al</AU>
<TI>GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>194</VL>
<PG>410-9</PG>
<IDENTIFIERS MODIFIED="2008-07-15 10:55:28 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-18 13:29:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, et al</AU>
<TI>Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>128</VL>
<PG>313-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-APRICOT-2004" MODIFIED="2008-09-23 13:20:12 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="APRICOT 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-15 14:47:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dore GJ, Torriani FJ, Rodriguez-Torres M, Brau N, Sulkowski M, Lamoglia RS, et al</AU>
<TI>Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection</TI>
<SO>AIDS</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>1555-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:47:40 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Secondary to Torriani (APRICOT)&lt;/p&gt;" NOTES_MODIFIED="2008-07-15 14:47:40 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornberger J, Torriani JF, Dieterich DT, Brau N, Sulkowski MS, Rodriguez-Torres M, et al</AU>
<TI>Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2006</YR>
<VL>36</VL>
<PG>283-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:17:00 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lissen E, Clumeck N, Sola, R, Mendes-Correa M, Montaner J, Nelson M, et al</AU>
<TI>Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection</TI>
<SO>AIDS</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>2175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:17:10 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al</AU>
<TI>Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy</TI>
<SO>AIDS</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>F21-F25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:17:29 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, et al</AU>
<TI>Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2008</YR>
<VL>47</VL>
<PG>36-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:46:42 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Secondary to Torriani (APRICOT)&lt;/p&gt;" NOTES_MODIFIED="2008-07-15 14:46:42 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Torres M, Gonzalez-Garcia J, Brau N, Sola N , Moreno S, Rockstroh J, et al</AU>
<TI>Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?</TI>
<SO>Journal of Medical Virology</SO>
<YR>2007</YR>
<VL>79</VL>
<PG>694-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:49:35 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Secondary to Torriani (APRICOT)&lt;/p&gt;" NOTES_MODIFIED="2008-07-15 14:49:35 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Torres M, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M, et al</AU>
<TI>Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study</TI>
<SO>Antimicrobial Agents and Chemiotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<PG>3997-4008</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:20:12 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Torriani FJ, Rockstroh J, Rodriguez-Torres M, Lissen E, Gonzalez J, Lazzarin A, et al</AU>
<TI>Final results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon-alfa-2a + ribavirin vs interferon-alfa-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection</TI>
<SO>11 th Conference on Retroviruses and Opportunistic Infections (CROI)</SO>
<YR>2004</YR>
<PG>112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:50:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<PG>438-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CORIST_x002d_ANRS-2003" MODIFIED="2008-08-22 12:47:25 +0200" MODIFIED_BY="Emanuela Marchesini" NAME="CORIST-ANRS 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-22 12:47:25 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salmon-Ceron D, Lassalle R, Pruvost A, Benech H, Bouvier-Alias M, Payan C, et al</AU>
<TI>Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>1295-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crespo-2007" MODIFIED="2008-07-15 14:52:17 +0200" MODIFIED_BY="[Empty name]" NAME="Crespo 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-07-15 14:52:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crespo M, Esteban J, Ribera E, Falco V, Sauleda S, Buti M, et al</AU>
<TI>Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients</TI>
<SO>AIDS</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>477-81</PG>
<IDENTIFIERS MODIFIED="2008-07-10 00:25:01 +0200" MODIFIED_BY="Emanuela Marchesini"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:51:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, et al</AU>
<TI>Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>228-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuster-2006" MODIFIED="2008-09-23 13:20:40 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Fuster 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-23 13:20:40 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaró J, et al</AU>
<TI>Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response</TI>
<SO>Antiviral Therapy</SO>
<YR>2006</YR>
<VL>11</VL>
<PG>473-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ICOS-2005" MODIFIED="2008-09-23 13:20:46 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="ICOS 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-23 13:20:46 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, et al</AU>
<TI>Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART</TI>
<SO>Antiviral Therapy</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>309-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laguno-2004" MODIFIED="2009-05-27 20:02:20 +0200" MODIFIED_BY="Emanuela Marchesini" NAME="Laguno 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-11 10:58:22 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, et al</AU>
<TI>Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2007</YR>
<VL>44</VL>
<PG>174-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:21:22 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez Tapias JM, et al</AU>
<TI>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients</TI>
<SO>AIDS</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>27-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laguno-2009" MODIFIED="2009-11-09 14:09:01 +0100" MODIFIED_BY="[Empty name]" NAME="Laguno 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-09 14:09:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A</AU>
<TI>Randomized trial comparing pegylated interferon-2b versus pegylated interferon-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>1</NO>
<PG>22-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puoti-2004" MODIFIED="2008-09-23 13:21:38 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Puoti 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-23 13:21:38 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puoti M, Zanini B, Quinzan GP, Ravasio L, Paraninfo G, Santantonio T, et al</AU>
<TI>A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>41</VL>
<PG>312-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIBAVIC-2004" MODIFIED="2009-09-07 10:03:03 +0200" MODIFIED_BY="[Empty name]" NAME="RIBAVIC 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, et al</AU>
<TI>Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors</TI>
<SO>AIDS</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>525-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:57:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Sadr F, Carrat F, Pol S, Hor E, Rosenthal E, Goujard C, et al</AU>
<TI>Risk factors for symptomatics for symptomatic mithocondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:59:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F, et al</AU>
<TI>Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1&#8211;coinfected subjects</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<PG>1375-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 14:58:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F, et al</AU>
<TI>Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment</TI>
<SO>Clinical Infectious Disesase</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>1806-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-05 16:32:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Sadr F, Lapidus N, Melchior JC, Ravaux I, Bensalem M, Rosa I, et al</AU>
<TI>Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-07 10:00:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Sadr, Lapidus N, Rosenthal E, Gerard L, Foltzer A, Perronne C, et al</AU>
<TI>Gamma glutamyltransferase elevation in HIV/hepatitis C virus&#8211;coinfected patients during Interferon&#8211;ribavirin combination therapy</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>4</NO>
<PG>429</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-27 19:19:07 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al</AU>
<TI>Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>23</NO>
<PG>2839-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-07 10:01:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrat F, Bedossa P, Lunel Fabiani F, Morand P, Pialoux G, Morand P, et al</AU>
<TI>Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfected patients</TI>
<SO>AIDS</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>1513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-10 00:48:01 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payan C, Pivert A, Morand P, Fafi-Kremer S, Carrat F, Poi S, et al</AU>
<TI>Rapid and early virological response to chronic hepatitis C treatment with interferon alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV coinfected patients</TI>
<SO>Gut</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>1111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-07 10:02:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perronne C, Carrat F, Bani Sadr F, Hor T, Morand P, Lunel F, et al</AU>
<TI>RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results</TI>
<SO>International Conference on AIDS</SO>
<YR>2002</YR>
<PG>LbOr16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:22:59 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, et al</AU>
<TI>Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients</TI>
<SO>11 Conference on Retroviruses and Opportunistic Infections (CROI)</SO>
<YR>2004</YR>
<PG>117Lb</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-07 10:03:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piroth L, Carrat F, Larrat S, Goderel I, Martha B, Payan C, et al</AU>
<TI>Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV&#8211;HCV co-infected patients on HCV therapy</TI>
<SO>Journal of Hepatology</SO>
<YR>2008</YR>
<VL>49</VL>
<PG>892&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-15 15:02:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pivert A, Payan C, Morand P, Fafi-Kremer S, Deshayes J, Carrat F, et al</AU>
<TI>Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV treated with interferon plus ribavirin</TI>
<SO>Journal Clinical Microbiology</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>417-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ROCO-2003" MODIFIED="2009-02-02 13:15:05 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="ROCO 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-18 10:10:07 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neau D, Galperine T, Legrand E, Pitard V, Neau-Cransac M, Moreau JF, et al</AU>
<TI>T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin</TI>
<SO>HIV Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>120-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-18 10:10:07 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neau D, Jouvencel AC, Legrand E, Trimoulet P, Galperine T, Chitty I, et al</AU>
<TI>Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients</TI>
<SO>Journal of Medical Virology</SO>
<YR>2003</YR>
<VL>71</VL>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-18 10:10:07 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neau D, Trimoulet P, Winnock M, Rullier A, Le Bail B, Lacoste D, et al</AU>
<TI>Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>1564-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sax-2001" MODIFIED="2008-08-22 12:47:41 +0200" MODIFIED_BY="Emanuela Marchesini" NAME="Sax 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-22 12:47:40 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sax H, Friedel A, Renner E, Streuerwald MH, Weber R for the Swiss HIV cohort study</AU>
<TI>Pilot study of interferon alpha with and without amantadine for the treatment of hepatitis C in HIV coinfected individuals on antiretroviral therapy</TI>
<SO>Infection</SO>
<YR>2001</YR>
<VL>29</VL>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHIRT-2003" MODIFIED="2008-08-18 10:51:05 +0200" MODIFIED_BY="Emanuela Marchesini" NAME="SHIRT 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-18 10:51:05 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Olmeda M, Soriano V, Asensi V, Morales D, Romero M, Ochoa A, et al</AU>
<TI>Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin</TI>
<SO>AIDS Research &amp; Human Retroviruses</SO>
<YR>2003</YR>
<VL>19</VL>
<PG>1083-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulkowski-2004" MODIFIED="2008-08-18 10:10:20 +0200" MODIFIED_BY="Emanuela Marchesini" NAME="Sulkowski 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-18 10:10:20 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulkowski MS, Felizarta F, Smith C, Slim J, Berggren R, Goodman R, et al</AU>
<TI>Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2004</YR>
<VL>35</VL>
<PG>464-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-09-23 13:32:53 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Brau-2004" MODIFIED="2008-09-23 13:31:18 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Brau 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-17 19:15:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brau N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, et al</AU>
<TI>Treatment of chronic hepatitis C in HIV/ HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>989-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-17 14:44:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostman J, Rodriguez-Torres M, Prokupek D, Bonacini M, Brau N, Giffen C, et al</AU>
<TI>Characteristics of HCV/HIV coinfected persons enrolled into a multicenter randomized double-blind placebo-controlled trial of ribavirin/interferon alpha 2b combination therapy</TI>
<SO>International Conference AIDS</SO>
<YR>2000</YR>
<VL>13</VL>
<PG>A0428</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:30:32 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="OTHER">
<AU>Kostman JR, Rodriguez-Torres M, Prokupek D, Bonacini M, Brau N, Hassanein T, et al</AU>
<TI>Results of a multicenter randomized double-blind, controlled trial of interferon alpha-2b/ribavirin combination therapy in HCV/HIV coinfected persons</TI>
<SO>http://www.amfar.org/binary-data/AMFAR_PDF/pdf/7.pdf</SO>
<YR>(accessed 23 September 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:31:18 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NOTES="&lt;p&gt;Page(s) missing&lt;/p&gt;" NOTES_MODIFIED="2008-09-23 13:31:18 +0200" NOTES_MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="OTHER">
<AU>Kostman JR, Rodriguez-Torres M, Prokupek D, Brau N, Bonacini M, Hassanein T, et al</AU>
<TI>Results of a multicentric randomized, double blind, controlled trial of interferon a-2b/ribavirin combination therapy in HCV/HIV co-infected persons</TI>
<SO>International AIDS Society Meetings</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-17 20:04:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulkowski MS</AU>
<TI>Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>906-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coral-2007" MODIFIED="2008-08-28 09:09:04 +0200" MODIFIED_BY="[Empty name]" NAME="Coral 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-22 12:47:14 +0200" MODIFIED_BY="Emanuela Marchesini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, et al</AU>
<TI>Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>704-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khalili-2005" MODIFIED="2008-09-23 13:32:26 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Khalili 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-23 13:32:26 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahlili M, Bernestein D, Lentz E, Barylski D, Hoffman-Terry M</AU>
<TI>Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2003</YR>
<VL>50</VL>
<PG>1148-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makris-1991" MODIFIED="2008-09-23 13:32:53 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Makris 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-09-23 13:32:53 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI</AU>
<TI>A randomized controlled trial of recombinant interferon-&#945; in chronic hepatitis C in Hemophiliacs</TI>
<SO>Blood</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>1</NO>
<PG>1672-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-07-17 19:44:16 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2008-07-22 12:51:13 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ANRSHC12-2003" MODIFIED="2008-07-22 12:27:37 +0200" MODIFIED_BY="[Empty name]" NAME="ANRSHC12 2003" YEAR="2003">
<IDENTIFIERS MODIFIED="2008-07-22 12:27:37 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-22 12:27:37 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00122616"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hoffmann_x002d_La-Roche-2006" MODIFIED="2008-07-18 13:12:33 +0200" MODIFIED_BY="[Empty name]" NAME="Hoffmann-La Roche 2006" YEAR="2006">
<IDENTIFIERS MODIFIED="2008-07-18 13:12:24 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-18 13:12:24 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00353418"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-HRN004-2005" MODIFIED="2008-07-22 12:07:34 +0200" MODIFIED_BY="[Empty name]" NAME="HRN004 2005" YEAR="2005">
<IDENTIFIERS MODIFIED="2008-07-18 12:27:11 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-18 12:27:07 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00215839"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-HRN005-2005" MODIFIED="2008-07-22 12:07:40 +0200" MODIFIED_BY="[Empty name]" NAME="HRN005 2005" YEAR="2005">
<IDENTIFIERS MODIFIED="2008-07-22 11:32:39 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-22 11:32:39 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00215891"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NIAID-2004" MODIFIED="2008-07-18 12:29:32 +0200" MODIFIED_BY="[Empty name]" NAME="NIAID 2004" YEAR="2004">
<IDENTIFIERS MODIFIED="2008-07-18 12:29:32 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-18 12:29:32 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00085917"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Perico-2007" MODIFIED="2008-07-22 12:06:58 +0200" MODIFIED_BY="[Empty name]" NAME="Perico 2007" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-07-22 12:06:58 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-22 12:06:58 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00526448"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-San-Cecilio-2005" MODIFIED="2008-07-21 18:21:52 +0200" MODIFIED_BY="[Empty name]" NAME="San Cecilio 2005" YEAR="2005">
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00612755"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Valencia-2008" MODIFIED="2008-07-18 12:58:09 +0200" MODIFIED_BY="[Empty name]" NAME="Valencia 2008" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-07-18 12:58:09 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-18 12:58:09 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00611819"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-09-28 13:40:23 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-09-28 13:40:23 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alter-1992" MODIFIED="2009-09-28 13:35:51 +0200" MODIFIED_BY="[Empty name]" NAME="Alter 1992" TYPE="JOURNAL_ARTICLE">
<AU>Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al</AU>
<TI>The natural history of community-acquired hepatitis C in the United States. The Sentinel Countries Chronic non-A, non-B Hepatitis Study Team</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<NO>27</NO>
<PG>1899-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benhamou-1999" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Benhamou 1999" TYPE="JOURNAL_ARTICLE">
<AU>Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al</AU>
<TI>Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>30</VL>
<PG>1054-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bica-2001" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Bica 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al</AU>
<TI>Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection</TI>
<SO>Clinical Infectious Diseses</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>492-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2005" MODIFIED="2009-09-28 13:35:37 +0200" MODIFIED_BY="[Empty name]" NAME="Brok 2005" TYPE="COCHRANE_REVIEW">
<AU>J Brok, LL Gluud, C Gluud</AU>
<TI>Ribavirin plus interferon versus interferon for chronic hepatitis C</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>Issue 2</NO>
<IDENTIFIERS MODIFIED="2008-09-23 14:05:31 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<IDENTIFIER MODIFIED="2008-09-23 14:05:31 +0200" MODIFIED_BY="Sarah Louise Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD005445"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daar-2001" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Daar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Daar ES, Lynn H, Donfield S, Gomperts E, O'Brien SJ, Hilgartner MW, et al</AU>
<TI>Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>183</VL>
<PG>589-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Bisceglie-2008" MODIFIED="2009-09-28 13:36:17 +0200" MODIFIED_BY="[Empty name]" NAME="Di Bisceglie 2008" TYPE="JOURNAL_ARTICLE">
<AU>Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al</AU>
<TI>Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>23</NO>
<PG>2429-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Martino-2001" MODIFIED="2009-09-28 13:36:49 +0200" MODIFIED_BY="[Empty name]" NAME="Di Martino 2001" TYPE="JOURNAL_ARTICLE">
<AU>Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al</AU>
<TI>The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>6</NO>
<PG>1193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dienstag-2006" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Dienstag 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dienstag JL, McHutchison JG</AU>
<TI>American Gastroenterological Association medical position statement on the management of hepatitis C</TI>
<SO>Gastroenterology</SO>
<YR>2006</YR>
<VL>130</VL>
<PG>225-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EACS-guidelines" MODIFIED="2009-09-07 10:52:39 +0200" MODIFIED_BY="[Empty name]" NAME="EACS guidelines" TYPE="JOURNAL_ARTICLE">
<AU>Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al</AU>
<TI>European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults</TI>
<SO>HIV Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>82-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eyster-1994" MODIFIED="2009-09-28 13:37:21 +0200" MODIFIED_BY="[Empty name]" NAME="Eyster 1994" TYPE="JOURNAL_ARTICLE">
<AU>Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ</AU>
<TI>Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>4</NO>
<PG>1020-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2006" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Gluud 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL</AU>
<TI>Bias in clinical intervention research</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>493-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2009" MODIFIED="2009-02-02 13:01:26 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Gluud 2009" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2009, Issue 1. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2001" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Graham 2001" TYPE="JOURNAL_ARTICLE">
<AU>Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al</AU>
<TI>Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2001</YR>
<VL>33</VL>
<PG>562-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greub-2000" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Greub 2000" TYPE="JOURNAL_ARTICLE">
<AU>Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al</AU>
<TI>Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV hepatitis C virus infection: the Swiss HIV Cohort study</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<PG>1800-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hadziyannis-2006" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Hadziyannis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al</AU>
<TI>Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>346-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-02-02 13:01:26 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Colloboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-2007" MODIFIED="2009-09-07 10:53:02 +0200" MODIFIED_BY="[Empty name]" NAME="Kim 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kim AI, Dorn A, Bouajram R, Saab S</AU>
<TI>The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis</TI>
<SO>HIV Medicine</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>312-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2009-08-27 11:34:14 +0200" MODIFIED_BY="Alfonso Iorio" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcellin-1994" MODIFIED="2009-09-28 13:37:51 +0200" MODIFIED_BY="[Empty name]" NAME="Marcellin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, et al</AU>
<TI>Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay</TI>
<SO>The Journal of Infectious Disease</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>2</NO>
<PG>433-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2009-02-02 13:05:20 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohsen-2002" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Mohsen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mohsen AH, Easterbrook P, Taylor CB, Norris S</AU>
<TI>Hepatitis C and HIV-1 coinfection</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>601-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myers-2002" MODIFIED="2009-09-28 13:38:15 +0200" MODIFIED_BY="[Empty name]" NAME="Myers 2002" TYPE="COCHRANE_REVIEW">
<AU>Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al</AU>
<TI>Interferon for interferon naive patients with chronic hepatitis C</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-08-27 11:04:41 +0200" MODIFIED_BY="Emanuela Marchesini">
<IDENTIFIER MODIFIED="2009-08-27 11:04:41 +0200" MODIFIED_BY="Emanuela Marchesini" TYPE="DOI" VALUE="10.1002/14651858.CD000370"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Olmelda-2003" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Olmelda 2003" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Olmeda M, Soriano V, Asensi V, Morales D, Romero M, Ochoa A, et al</AU>
<TI>Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin</TI>
<SO>AIDS Research and Human Retroviruses</SO>
<YR>2003</YR>
<VL>19</VL>
<PG>1083-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pineda-2005" MODIFIED="2009-09-28 13:38:38 +0200" MODIFIED_BY="[Empty name]" NAME="Pineda 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pineda JA, Romero-Gómez M, Díaz-García F, Girón-González JA, Montero JL, Torre-Cisneros J, et al</AU>
<TI>HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis</TI>
<SO>Hepatology</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>4</NO>
<PG>779-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poynard-1996" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Poynard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al</AU>
<TI>Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>778-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rockstroh-2004" MODIFIED="2009-09-07 10:54:34 +0200" MODIFIED_BY="[Empty name]" NAME="Rockstroh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rockstroh JK, Spengler U</AU>
<TI>HIV and hepatitis C virus co-infection</TI>
<SO>The Lancet Infectious Diseases</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>437-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rockstroh-2005" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Rockstroh 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al</AU>
<TI>Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>192</VL>
<PG>992-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez-2001" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Rodriguez 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Rosado R, Perez-Olmeda M, Garcia-Samaniego J, Soriano V</AU>
<TI>Management of hepatitis C in HIV-infected persons</TI>
<SO>Antiviral Research</SO>
<YR>2001</YR>
<VL>52</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2009-02-02 12:58:19 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2009-02-02 13:05:20 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serfaty-2001" MODIFIED="2009-09-28 13:39:00 +0200" MODIFIED_BY="[Empty name]" NAME="Serfaty 2001" TYPE="JOURNAL_ARTICLE">
<AU>Serfaty L, Costagliola D, Wendum D, Picard O, Meyohas MC, Girard PM, et al</AU>
<TI>Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study</TI>
<SO>AIDS</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>15</NO>
<PG>2011-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simin-2007" MODIFIED="2009-07-03 19:48:45 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Simin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Simin M, Brok J, Stimac D, Gluud C, Gluud LL</AU>
<TI>Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>1153-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soriano-2002" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Soriano 2002" TYPE="JOURNAL_ARTICLE">
<AU>Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al</AU>
<TI>Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel</TI>
<SO>AIDS</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>813-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soto-1997" MODIFIED="2009-09-28 13:39:24 +0200" MODIFIED_BY="[Empty name]" NAME="Soto 1997" TYPE="JOURNAL_ARTICLE">
<AU>Soto B, Sánchez-Quijano A, Rodrigo L, del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al</AU>
<TI>Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis</TI>
<SO>Journal of Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas--2000" MODIFIED="2009-09-28 13:40:00 +0200" MODIFIED_BY="[Empty name]" NAME="Thomas  2000" TYPE="JOURNAL_ARTICLE">
<AU>Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al</AU>
<TI>The natural history of hepatitis C virus infection: host viral, and environmental factors</TI>
<SO>The Journal of American Medical Association</SO>
<YR>2000</YR>
<VL>284</VL>
<NO>4</NO>
<PG>450-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-VA-guidelines" MODIFIED="2008-09-23 14:08:52 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="VA guidelines" TYPE="JOURNAL_ARTICLE">
<AU>Yee HS, Currie SL, Darling JM, Wright TL</AU>
<TI>Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<PG>2360-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villano-1999" MODIFIED="2009-09-28 13:40:23 +0200" MODIFIED_BY="[Empty name]" NAME="Villano 1999" TYPE="JOURNAL_ARTICLE">
<AU>Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL</AU>
<TI>Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>3</NO>
<PG>908-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waldrep-2000" MODIFIED="2008-09-23 14:08:51 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Waldrep 2000" TYPE="JOURNAL_ARTICLE">
<AU>Waldrep TW, Summers KK, Chiliade PA</AU>
<TI>Coinfection with HIV and HCV: more questions than answers?</TI>
<SO>Pharmacotherapy</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>1499-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2009-02-02 13:05:20 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-11-09 22:46:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-09 22:46:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-ACTG-2004">
<CHAR_METHODS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: estimated required sample size was 132 patients.</P>
<P>Multicentre trial with 21 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients:</P>
<UL>
<LI>Median age: 45 years.</LI>
<LI>Proportion of men: 82%</LI>
<LI>Proportion with hepatitis C virus genotype 1: 78%</LI>
<LI>Proportion with cirrhosis: 10%.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon 180 microgram weekly plus ribavirin 600 to 1000 mg daily</LI>
<LI>interferon 6 million units three times weekly for 12 weeks then 3 million units three times weekly (for remaining treatment duration) plus ribavirin for 600 to 1000 mg daily.</LI>
</UL>
<P>The dose of ribavirin was increased monthly from 600 to 1000 mg daily in both treatment groups.</P>
<P>The treatment duration was 48 weeks for patients with a virological or histological response after 24 weeks of treatment. All other patients were treated for 24 weeks</P>
<P>Follow-up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up. Adverse events at end of treatment and follow-up evaluation.</P>
<P>Liver biopsies were performed before and after treatment. However, histological response for patients stratified by treatment group is only reported for patients without a sustained virological response. These data are not included in the meta-analysis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Official title: The Adult AIDS Clinical Trials Group (ACTG) A5071</P>
<P>Funded by: National Institutes of Health.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-APRICOT-2004">
<CHAR_METHODS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Sample size calculation performed, but required sample size not specifically reported.</P>
<P>Multicentre trial with 95 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients:</P>
<UL>
<LI>Mean age: 40 years</LI>
<LI>Proportion of men: 81%</LI>
<LI>Proportion with hepatitis C genotype 1: 61%</LI>
<LI>Proportion with cirrhosis: 45%.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon 180 microgram once weekly plus oral ribavirin 800 mg daily</LI>
<LI>peginterferon 180 microgram once weekly plus ribavirin placebo</LI>
<LI>interferon 3 million units three times weekly plus ribavirin 800 mg daily.</LI>
</UL>
<P>Treatment duration was 48 weeks in all treatment arms.</P>
<P>Follow-up for 24 weeks after the end of treatment.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
<P>Hepatic decompensation occurred in 14 of the 860 patients who received at least one dose of the allocated treatment. All 14 patients had cirrhosis. Six of the 14 patients died.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-06 12:39:16 +0200" MODIFIED_BY="[Empty name]">
<P>Official title AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT).</P>
<P>Funded by: Roche, Basel, Switzerland.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-06 15:06:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<CHAR_METHODS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: estimated required sample size was 132 patients.</P>
<P>Multicentre trial with 17 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients:</P>
<UL>
<LI>Mean age:36 years.</LI>
<LI>Proportion of men: 60%</LI>
<LI>Proportion with hepatitis C genotype 1: 50%</LI>
<LI>Proportion with cirrhosis: not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>Interferon 3 million units 3 times weekly plus ribavirin 1000 mg or 1200 mg</LI>
<LI>No treatment</LI>
</UL>
<P>Treatment duration was 12 weeks.</P>
<P>Follow-up after treatment: 40 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measure: difference of plasma HIV-1 RNA level between baseline and 12 weeks.</P>
<P>Secondary outcome measures: virological response, clinical and laboratory.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-06 15:06:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Official Title: Interferon-Ribavirin in Association with Stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients co-infected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial</P>
<P>Funded by: French agencies for research on AIDS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Crespo-2007">
<CHAR_METHODS MODIFIED="2008-08-06 12:40:32 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: estimated required sample size was 116 patients.</P>
<P>Single centre trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon.</P>
<P>Characteristics of included patients:</P>
<UL>
<LI>Mean age: 38 years.</LI>
<LI>Proportion of men: 69%</LI>
<LI>Proportion with hepatitis C genotype 1: 48%</LI>
<LI>Proportion with cirrhosis: not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients were randomised to</P>
<UL>
<LI>peginterferon 1.5 microgram/kg once weekly plus ribavirin 800 mg daily</LI>
</UL>
<UL>
<LI>interferon 3 million units three times weekly plus ribavirin 800 mg daily.</LI>
</UL>
<P>Patients with hepatitis C genotype 1 or 4 and a virological response after 24 weeks were treated for 48 weeks. All remaining patients were treated for 24 weeks.</P>
<P>Follow-up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up</P>
<P>Liver biopsies were not performed after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Funded by: Fundacio Privada Catalana de l'Hemofilia, Barcelona, Fondo para la Investigacion y la Prevencion del SIDA, Spain, Red Nacional de Investigación en Hepatología y Gastroenterologia, and the Red de Investigación en SIDA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-29 13:38:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Fuster-2006">
<CHAR_METHODS MODIFIED="2008-08-29 08:59:46 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Sample size calculation: not performed.</P>
<P>Multicentre trial with 10 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV, and no virological response to treatment with peginterferon plus ribavirin for 12 weeks. None were treated with interferon before the present trial.</P>
<P>Characteristics of included patients:</P>
<UL>
<LI>Mean age: not reported (baseline population 39 years).</LI>
<LI>Proportion of men: 89%</LI>
<LI>Proportion with hepatitis C genotype 1: not reported (baseline population 48%).</LI>
<LI>Proportion with cirrhosis: not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-29 13:38:38 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon 180 microgram once weekly plus ribavirin 800 mg daily for 24 weeks</LI>
<LI>peginterferon 180 microgram once weekly plus ribavirin 800 mg daily for 48 weeks.</LI>
</UL>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
<P>Adverse events are reported for all patients without specification of treatment group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Funded by: Roche Farma, Spain and Red Tematica Cooperative de Investigacion en SIDA, Spain, and Instituto Carlos III, Spain.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-29 13:38:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-ICOS-2005">
<CHAR_METHODS MODIFIED="2008-08-06 12:49:18 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: not reported.</P>
<P>Multicentre trial with 26 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 14:10:50 +0200" MODIFIED_BY="[Empty name]">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients</P>
<UL>
<LI>Mean age: 39 years.</LI>
<LI>Proportion of men: 83%</LI>
<LI>Proportion with hepatitis C genotype 1: 44%</LI>
<LI>Proportion with cirrhosis: 16%.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-29 13:38:48 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon 1.5 microgram/kg once weekly plus ribavirin 800 mg daily</LI>
<LI>peginterferon 1.5 microgram/kg once weekly.</LI>
</UL>
<P>All patients were treated for 48 weeks</P>
<P>Follow-up after treatment: 24 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
<P>No deaths reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Funding: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Laguno-2004">
<CHAR_METHODS MODIFIED="2008-08-06 12:48:18 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: estimated required sample size was 90 patients.</P>
<P>Single centre trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients</P>
<UL>
<LI>Mean age: 40 years.</LI>
<LI>Proportion of men: 68%</LI>
<LI>Proportion with hepatitis C genotype 1: 49%</LI>
<LI>Proportion with cirrhosis: 33%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon 100 or 150 microgram once weekly adjusted by body weight plus ribavirin 800 to 1200 mg daily adjusted by body weight</LI>
<LI>interferon 3 million units three times weekly plus ribavirin (dose as above).</LI>
</UL>
<P>Patients with hepatitis C genotype 2 or 3 and a low viral load were treated for 24 weeks. Remaining patients were treated for 48 weeks.</P>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
<P>No cases of hepatic decompensation occurred.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Funded by Schering-Plough, Generalitat de Catalunya (DURSI), and the Red Tematica de Investigacion en SIDA, Spain.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 22:43:34 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Laguno-2009">
<CHAR_METHODS MODIFIED="2009-05-28 10:54:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open label multicentre randomised clinical trial.</P>
<P>Sample size (164 subjects, 0.8 power) estimated to find out a significant difference of 50% with the best group getting a 40% SVR rate</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-06 15:06:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Patients with chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin</P>
<P>Characteristics of included patients</P>
<UL>
<LI>Mean age: 40 years.</LI>
<LI>Proportion of men: 72%</LI>
<LI>Proportion with hepatitis C genotype 1: 45%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-28 00:56:04 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon alpha-2a 180 micrograms once weekly plus ribavirin 800 to 1200 mg daily</LI>
<LI>peginterferon alpha-2b 80-150 micrograms once weekly plus ribavirin 800 to 1200 mg daily</LI>
</UL>
<P>Patients were treated for 48 weeks.</P>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-28 00:57:46 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Sustained virological response at end of treatment and after completion of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 22:43:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The study was probably underpowered to detect a plausible difference, since a 50% difference in the effect size was not likely.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Puoti-2004">
<CHAR_METHODS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: 64 patients.</P>
<P>Multicentre trial with 15 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated.</P>
<P>Characteristics of included patients:</P>
<UL>
<LI>Mean age: 37 years.</LI>
<LI>Proportion of men: 72%</LI>
<LI>Proportion with hepatitis C genotype 1: 49%</LI>
<LI>Proportion with cirrhosis: not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>interferon alfa 2a 3 million unit thrice weekly</LI>
<LI>interferon alfa 2a 3 million units daily plus amantadine 200 mg daily.</LI>
</UL>
<P>Treatment duration was 24 to 48 weeks according to HCV genotype.</P>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-26 11:19:38 +0200" MODIFIED_BY="Emanuela Marchesini"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-29 13:38:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-RIBAVIC-2004">
<CHAR_METHODS MODIFIED="2008-08-06 12:47:26 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: performed, but required sample size not specified.</P>
<P>Multicentre trial with 71 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-27 19:32:57 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients</P>
<UL>
<LI>Mean age: 40 years.</LI>
<LI>Proportion of men: 74%</LI>
<LI>Proportion with hepatitis C genotype 1 or 4: 61%</LI>
<LI>Proportion with cirrhosis (or bridging fibrosis): 39%.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-29 13:38:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>peginterferon 1.5 microgram/kg body weight once weekly plus ribavirin 800 mg daily</LI>
<LI>interferon 3 million units three times weekly plus ribavirin 800 mg daily.</LI>
</UL>
<P>All patients were treated for 48 weeks.</P>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-06 12:47:34 +0200" MODIFIED_BY="[Empty name]">
<P>Funded by Agence Nationale de Recherches sur le SIDA. Schering-Plough provided the drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-ROCO-2003">
<CHAR_METHODS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Sample size calculation: 148 patients.</P>
<P>Multicentre trial with 18 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-18 12:25:28 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<UL>
<LI>Median age: 36 years</LI>
<LI>Proportion of men: 65%</LI>
<LI>Proportion with hepatitis C genotype 1:41%</LI>
<LI>Proportion with cirrhosis: 7%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>Interferon alfa 2a six million units three times weekly for 24 weeks, followed by three million unit three times weekly for 24 weeks.</LI>
<LI>Interferon alfa 2a: nine million unit daily for two weeks, followed by three million units daily for 22 weeks, followed by three million unit three times weekly for 24 weeks.</LI>
</UL>
<P>Both plus ribavirin 800 mg daily from week 16 for non responder patients.</P>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
<P>Histological response to HCV-therapy was available only for 31/68 patients. Data not included in the analysis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio">
<P>Official title: Comparison of 2 regimens that include interferon-&#945;-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus co infected patients.</P>
<P>Funded by: Roche and Association pour le Development de l'Enseignement et des Recherches auprès des Universities, des Centres de Reserche et des Enterprises d'Aquitaine.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Sax-2001">
<CHAR_METHODS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: not reported.</P>
<P>Single centre trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<P>Characteristics of included patients</P>
<UL>
<LI>Mean age: 40 years.</LI>
<LI>Proportion of men 60%</LI>
<LI>Proportion with hepatitis C genotype 1: not reported</LI>
<LI>Proportion with cirrhosis (or bridging fibrosis): not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to</P>
<UL>
<LI>Interferon alfa 2a six million units three times weekly for 24 weeks, followed by three million unit three times weekly plus amantadine for 24 weeks</LI>
<LI>Interferon alfa 2a six million units three times weekly for 24 weeks, followed by three million unit three times weekly for 24 weeks.</LI>
</UL>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Funded by: Swiss National Science Foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-SHIRT-2003">
<CHAR_METHODS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: not reported.</P>
<P>Multicentre trial with 13 clinical site. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-18 12:32:07 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<UL>
<LI>Mean age: 37 years</LI>
<LI>Proportion of men: 79%</LI>
<LI>Proportion with hepatitis C genotype 1 or 4: 66%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to:</P>
<UL>
<LI>Interferon alfa 2a: five million units daily for firs 6 weeks, followed by three million unit three times weekly for 18 weeks</LI>
<LI>Interferon alfa 2a: three million unit three times weekly for 24 weeks</LI>
</UL>
<P>Both plus ribavirin 800 mg oid.</P>
<P>Follow-up after treatment: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Official title: Treatment of chronic hepatitis C in HIV-infected patients with interferon &#945;.2b plus ribavirin</P>
<P>Funded by: Istitutos de Salud Carlos III, Madrid 28029, Spain and in part by AIES, RIS (project 173), RTIC G03/015 and CAM.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 22:46:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sulkowski-2004">
<CHAR_METHODS MODIFIED="2009-11-09 22:46:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Sample size calculation: not reported.</P>
<P>Multicentre trial with 65 clinical sites.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-18 12:43:59 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Included patients had chronic hepatitis C and stable HIV. None were previously treated with interferon or ribavirin.</P>
<UL>
<LI>Mean age: 44 years</LI>
<LI>Proportion of men: 90%</LI>
<LI>Proportion with hepatitis C genotype 1:73%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Patients were randomised to:</P>
<UL>
<LI>Interferon alfa 2b: three million unit daily</LI>
<LI>Interferon alfa 2b: three million unit three times weekly</LI>
</UL>
<P>Both plus Ribavirin 800 mg daily</P>
<P>The treatment duration was 48 weeks</P>
<P>Follow-up after treatment: 24 week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-29 13:39:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Primary outcome measures: virological response at end of treatment and after completion of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Funded by: Schering-Plough Corporation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>HIV = human immunodeficiency virus.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-07-17 14:47:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brau-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-17 14:47:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial on interferon plus ribavirin versus interferon plus placebo for patients with chronic hepatitis C and HIV. After 12 weeks, patients in the placebo group were crossed over to interferon plus ribavirin if they did not respond to treatment (had detectable hepatitis C virus RNA).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coral-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial on peginterferon 270 microgram/week for 4 weeks followed by 8 weeks of peginterferon 180 microgram/week plus ribavirin versus peginterferon 180 microgram/week plus ribavirin. Primary outcome was early virological response.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khalili-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Trial on peginterferon and ribavirin for patients with hepatitis C and HIV. The trial was excluded since patients without a virological response to the allocated treatment with peginterferon plus ribavirin or placebo were withdrawn from the trial 10 weeks after randomisation. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Makris-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised trial on interferon versus no treatment in haemophilic patients. Primary outcome measure was normalization of alanine aminotransferase by the end of treatment sustained for at least 1 month.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-07-17 20:04:25 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-10-29 13:37:40 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-07-22 12:31:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ANRSHC12-2003">
<CHAR_STUDY_NAME MODIFIED="2008-07-22 12:28:38 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy of pegylated interferon on liver fibrosis in co-infected patient with HIV and C hepatitis who failed to active treatment for HCV. ANRSHC12 Fibrostop.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-22 12:28:44 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-22 12:29:31 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with chronic hepatitis C and HIV who did not respond to antiviral treatment for hepatitis C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 12:29:49 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon versus no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 12:30:39 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is improvement of fibrosis score (METAVIR).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:30:50 +0200" MODIFIED_BY="[Empty name]">
<P>July 2003.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-22 12:31:01 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator Dr Jean Marc Chapplain, Hopital Pontchaillou, Rennes France.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-08-29 09:03:07 +0200" MODIFIED_BY="Emanuela Marchesini" STUDY_ID="STD-Hoffmann_x002d_La-Roche-2006">
<CHAR_STUDY_NAME MODIFIED="2008-08-29 09:03:07 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>A randomized multicenter, double blinded, phase IV study comparing the safety and efficacy of pegasys 180 µg plus copegus 1000 or 1200 mg to the currently approved combination of pegasys 180 µg plus copegus 800 mg in interferon-naïve patients with chronic hepatitis C genotype 1 virus infection coi.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-18 13:13:06 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-22 11:48:44 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with chronic hepatitis C genotype 1 and HIV not previously treated with interferon or ribavirin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-18 13:14:14 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon plus low or high dose ribavirin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 12:15:07 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is loss of hepatitis C virus RNA 72 weeks after treatment is initiated.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:11 +0200" MODIFIED_BY="[Empty name]">
<P>June 2006.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-22 11:23:48 +0200" MODIFIED_BY="[Empty name]">
<P>Hoffmann-La Roche +1 973 235 5000.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HRN004-2005">
<CHAR_STUDY_NAME MODIFIED="2008-07-17 20:10:39 +0200" MODIFIED_BY="[Empty name]">
<P>A multi-center, randomized, open-label, phase IIIb study investigating the safety and efficacy of peginterferon a-2a plus ribavirin for the treatment of chronic hepatitis C infection in HIV infected persons who have failed to achieve a sustained virologic response following previous interferon therapy.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-18 12:31:36 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-17 20:12:06 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with chronic hepatitis C and HIV coinfection who did not respond (had detectable hepatitis C virus RNA) to treatment with interferon alone or with ribavirin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon alone or with ribavirin adjusted according to body weight.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 11:49:41 +0200" MODIFIED_BY="[Empty name]">
<P>Primary objective described as assessment of efficacy and safety (primary outcome measure not specified).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:16 +0200" MODIFIED_BY="[Empty name]">
<P>September 2005. </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-18 12:40:34 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator Dr D Dietrich. </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-07-17 20:14:14 +0200" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-10-29 13:37:40 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-HRN005-2005">
<CHAR_STUDY_NAME MODIFIED="2008-07-22 11:36:41 +0200" MODIFIED_BY="[Empty name]">
<P>PEG-interferon a-2b + ribavirin for treatment of chronic hepatitis C infection in HIV-infected persons not previously treated with interferon.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-22 11:36:48 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-22 11:37:32 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with chronic hepatitis C and HIV coinfection who have not previously been treated with interferon or ribavirin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 11:38:51 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon plus ribavirin for 48 or 72 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 12:13:35 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is undetectable hepatitis C virus RNA 24 weeks after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:21 +0200" MODIFIED_BY="[Empty name]">
<P>September 2005. </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-10-29 13:37:40 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Principal investigator Dr Mark Sulkowski (msulkowski@jhmi.edu).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-28 10:55:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-NIAID-2004">
<CHAR_STUDY_NAME MODIFIED="2009-05-28 10:55:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>A randomised controlled trial to evaluate the safety and efficacy of twice-weekly peginterferon alfa 2a and ribavirin induction therapy for chronic hepatitis C in patients who are coinfected with HIV-1.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-18 12:31:47 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 09:03:43 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Patients with chronic hepatitis C and HIV coinfection who have not previously been treated with interferon or ribavirin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-18 12:39:32 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon once or twice weekly plus ribavirin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-18 12:37:56 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is treatment response (not specified further).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:25 +0200" MODIFIED_BY="[Empty name]">
<P>June 2004. </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-18 12:35:24 +0200" MODIFIED_BY="[Empty name]">
<P>http://clinicalstudies.info.nih.gov/detail/B_2004-I-0187.html</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio" STUDY_ID="STD-Perico-2007">
<CHAR_STUDY_NAME MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio">
<P>Open, multicentre, randomised phase IV trial to evaluate efficacy/safety to extend treatment duration with peginterferon alfa-2a+high dose of ribavirin supporting erythropoietinin treatment of CHC in HIV-HCV patients who not clear virus at week 4.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-22 12:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 09:04:05 +0200" MODIFIED_BY="Emanuela Marchesini">
<P>Patients with chronic hepatitis C and HIV coinfection who have not previously been treated with interferon or ribavirin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 12:12:22 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon plus low or high dose ribavirin with epoetin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 12:14:45 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is undetectable hepatitis C virus RNA 24 weeks after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:30 +0200" MODIFIED_BY="[Empty name]">
<P>June 2007. </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-22 12:17:10 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator Dr Vicente Soriano, Hospital Carlos III. Madrid. Spain.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-07-22 12:18:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-San-Cecilio-2005">
<CHAR_STUDY_NAME MODIFIED="2008-07-21 18:18:31 +0200" MODIFIED_BY="[Empty name]">
<P>Open, randomised, multicenter phase IV study to evaluate efficacy and safety to extend treatment 24 weeks in co-infected HIV-HCV patients genotype 1 and/or 4.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-21 18:18:37 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 18:19:06 +0200" MODIFIED_BY="[Empty name]">
<P>Patiens with hepatitis C genotype 1 or 4 and HIV coinfection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 18:20:01 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon alfa plus ribavirin for 24 or 48 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 12:15:45 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is undetectable hepatitis C virus RNA 24 weeks after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:35 +0200" MODIFIED_BY="[Empty name]">
<P>October 2005. </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-22 12:16:15 +0200" MODIFIED_BY="[Empty name]">
<P>Primary investigator José Hernández-Quero, Hospital Clinico Universitario, San Cecilio, Spain.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-07-22 12:18:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valencia-2008">
<CHAR_STUDY_NAME MODIFIED="2008-07-18 12:59:43 +0200" MODIFIED_BY="[Empty name]">
<P>Open, randomized and multicenter phase IV study to compare the efficacy and safety of two different treatments duration 24 versus 48 weeks in chronic hepatitis C genotypes 2 and/or 3 co-infected HIV-HCV patients.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-07-18 12:59:50 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 18:22:44 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with chronic hepatitis C genotype 2 or 3 and HIV-1 who have not previously been treated with interferon or ribavirin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-18 13:01:43 +0200" MODIFIED_BY="[Empty name]">
<P>Peginterferon plus ribavirin for 24 or 48 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-22 12:15:59 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure is undetectable hepatitis C virus RNA 24 weeks after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-07-22 12:18:43 +0200" MODIFIED_BY="[Empty name]">
<P>November 2005. </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-07-22 12:16:21 +0200" MODIFIED_BY="[Empty name]">
<P>Dr Enrique Ortega, Hospital General Universitario de Valencia, Spain.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>HCV = hepatitis C virus <BR/>HIV = human immunodeficiency virus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-09 22:42:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-25 10:07:37 +0200" MODIFIED_BY="Emanuela Marchesini" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ACTG-2004">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-APRICOT-2004">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Crespo-2007">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Fuster-2006">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-01 14:19:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ICOS-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Laguno-2004">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 10:53:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Laguno-2009">
<DESCRIPTION>
<P>Computer generated random table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Puoti-2004">
<DESCRIPTION>
<P>Described as stratified by genotype and blocked by five.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-05 15:44:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RIBAVIC-2004">
<DESCRIPTION>
<P>Computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 10:55:04 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-ROCO-2003">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-SHIRT-2003">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Sax-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Sulkowski-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-25 10:07:37 +0200" MODIFIED_BY="Emanuela Marchesini" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ACTG-2004">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-APRICOT-2004">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Crespo-2007">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Fuster-2006">
<DESCRIPTION>
<P>Allocation performed by independent investigator. The allocation sequence and consequently upcoming treatment assignments were kept separate from other investigators and patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-05 15:28:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ICOS-2005">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Laguno-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 10:53:17 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Laguno-2009">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Puoti-2004">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-05 15:44:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RIBAVIC-2004">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ROCO-2003">
<DESCRIPTION>
<P>Central randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-SHIRT-2003">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Sax-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Sulkowski-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-25 10:07:37 +0200" MODIFIED_BY="Emanuela Marchesini" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:49:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-ACTG-2004">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-APRICOT-2004">
<DESCRIPTION>
<P>Sponsors, investigators, and patients were blinded regarding the allocation to ribavirin or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:49:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:49:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Crespo-2007">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-05 13:26:47 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuster-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:49:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-ICOS-2005">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:49:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Laguno-2004">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:50:11 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Laguno-2009">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:50:17 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Puoti-2004">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-27 19:33:50 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="YES" STUDY_ID="STD-RIBAVIC-2004">
<DESCRIPTION>
<P>Assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:55:07 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-ROCO-2003">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:50:45 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-SHIRT-2003">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:50:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Sax-2001">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-28 10:50:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Sulkowski-2004">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-10-29 13:38:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ACTG-2004">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-APRICOT-2004">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Crespo-2007">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-29 13:38:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Fuster-2006">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ICOS-2005">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Laguno-2004">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-28 01:00:13 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="YES" STUDY_ID="STD-Laguno-2009">
<DESCRIPTION>
<P>Intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-28 10:50:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Puoti-2004">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-29 13:38:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-RIBAVIC-2004">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ROCO-2003">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-SHIRT-2003">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-29 13:03:16 +0200" MODIFIED_BY="Alfonso Iorio" RESULT="NO" STUDY_ID="STD-Sax-2001">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-29 13:37:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sulkowski-2004">
<DESCRIPTION>
<P>Losses to follow-up: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-25 10:07:37 +0200" MODIFIED_BY="Emanuela Marchesini" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ACTG-2004">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-APRICOT-2004">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Crespo-2007">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Fuster-2006">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ICOS-2005">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Laguno-2004">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 01:00:37 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="UNKNOWN" STUDY_ID="STD-Laguno-2009">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 10:54:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Puoti-2004">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-06 12:47:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RIBAVIC-2004">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 11:11:11 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="YES" STUDY_ID="STD-ROCO-2003">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 11:35:26 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="UNKNOWN" STUDY_ID="STD-SHIRT-2003">
<DESCRIPTION>
<P>Withdrawals: clearly described and considered in the statistical analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Sax-2001">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Sulkowski-2004">
<DESCRIPTION>
<P>Primary outcome measure specified and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-11-09 22:42:07 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 22:42:07 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-ACTG-2004">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-APRICOT-2004">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-CORIST_x002d_ANRS-2003">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Crespo-2007">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Fuster-2006">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-ICOS-2005">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Laguno-2004">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-28 10:50:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Laguno-2009">
<DESCRIPTION>
<P>Two authors are industry sponsored, but the trial is financially supported by a no-profit organization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:10 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Puoti-2004">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-06 12:45:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RIBAVIC-2004">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 11:15:11 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="YES" STUDY_ID="STD-ROCO-2003">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 11:36:11 +0200" MODIFIED_BY="Emanuela Marchesini" RESULT="YES" STUDY_ID="STD-SHIRT-2003">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Sax-2001">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 16:50:11 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Sulkowski-2004">
<DESCRIPTION>
<P>No other apparent biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-10-29 13:36:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-10-29 13:36:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2008-08-06 13:10:49 +0200" MODIFIED_BY="[Empty name]">Mortality</TITLE>
<TABLE COLS="3" ROWS="15">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Trial</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Overall mortality</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Causes of death</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ACTG-2004" TYPE="STUDY">ACTG 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>One patient in the trial died due to Hodgkin's<SUP> </SUP>disease. The allocated treatment group of this patient is not reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mortality rates are reported separately for all treatment groups. However, the causes of death in relation to treatment group is only reported for two patients. One patient in the interferon group died of respiratory failure. One patient in the peginterferon group committed suicide. Six patients died of liver failure. The allocated treatment group of these patients is not reported. The causes of death is not reported for the remaining four patients.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Crespo-2007" TYPE="STUDY">Crespo 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Two patients with compensated cirrhosis died due to lactic acidosis and sepsis. The other patient had compensated cirrhosis at randomisation, but died due to increasing liver failure. Both patients were randomised to interferon plus ribavirin.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Fuster-2006" TYPE="STUDY">Fuster 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>One patient died due to an acute myocardial infarction. The allocated treatment group of this patient is not reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Seven deaths were reported. Among patients randomised to peginterferon, 2 died from liver failure, 1 from neuroendocrinecarcinoma, 1 from vulvar cancer, and 1 from nitrate propyl overdose. Among patients randomised to interferon, 1 died from liver failure and 1 from liver cancer.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ICOS-2005" TYPE="STUDY">ICOS 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ROCO-2003" TYPE="STUDY">ROCO 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-SHIRT-2003" TYPE="STUDY">SHIRT 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Sulkowski-2004" TYPE="STUDY">Sulkowski 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Sax-2001" TYPE="STUDY">Sax 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-CORIST_x002d_ANRS-2003" TYPE="STUDY">CORIST-ANRS 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Puoti-2004" TYPE="STUDY">Puoti 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No deaths reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="3" VALIGN="TOP">
<P>Total all cause mortality: 23 of 2111 patients.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-08-06 13:10:49 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-11-09 22:56:45 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2009-11-09 22:49:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Peginterferon plus ribavirin versus interferon plus ribavirin</NAME>
<DICH_OUTCOME CHI2="56.826872356784335" CI_END="2.5105456159379465" CI_START="1.9990649277153614" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2402552734568237" ESTIMABLE="YES" EVENTS_1="733" EVENTS_2="320" I2="66.56511398214991" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.39976811679586977" LOG_CI_START="0.3008268998162566" LOG_EFFECT_SIZE="0.35029750830606315" METHOD="MH" MODIFIED="2009-11-09 22:49:12 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="1.2155276894798561E-5" P_Q="0.0" P_Z="8.569199871662421E-44" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1999" TOTAL_2="1969" WEIGHT="500.0" Z="13.878351633687146">
<NAME>Sustained virological response</NAME>
<GROUP_LABEL_1>Peginterferon ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Interferon ribavirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN ribavirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.961781799180272" CI_END="2.7472424778555857" CI_START="1.8447309136070646" DF="4" EFFECT_SIZE="2.2512048165537206" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="108" I2="69.14004523473025" ID="CMP-001.01.01" LOG_CI_END="0.4388969929288326" LOG_CI_START="0.2659330256395596" LOG_EFFECT_SIZE="0.3524150092841961" MODIFIED="2008-08-06 16:32:26 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.011464078093909591" P_Z="1.3840317331964845E-15" STUDIES="5" TAU2="0.0" TOTAL_1="673" TOTAL_2="667" WEIGHT="100.0" Z="7.986874221648487">
<NAME>All patients</NAME>
<DICH_DATA CI_END="4.885487564691511" CI_START="1.0678711616618684" EFFECT_SIZE="2.284090909090909" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6889079121875934" LOG_CI_START="0.028518858353047124" LOG_EFFECT_SIZE="0.35871338527032026" ORDER="165" O_E="0.0" SE="0.3879157992009504" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.15047866726971204" WEIGHT="7.316488963574306"/>
<DICH_DATA CI_END="4.804495417566599" CI_START="2.4060799304196143" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="34" LOG_CI_END="0.6816477834981504" LOG_CI_START="0.3813100505863598" LOG_EFFECT_SIZE="0.5314789170422551" MODIFIED="2008-08-06 16:32:26 +0200" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.17641987100814083" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.03112397088652905" WEIGHT="31.384758521262082"/>
<DICH_DATA CI_END="3.385527380489774" CI_START="1.298729642821236" EFFECT_SIZE="2.096875" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5296263305090261" LOG_CI_START="0.11351875318914606" LOG_EFFECT_SIZE="0.32157254184908607" ORDER="167" O_E="0.0" SE="0.2444236506834247" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.05974292101341282" WEIGHT="14.621983954250682"/>
<DICH_DATA CI_END="4.073311749878888" CI_START="1.0963601132799232" EFFECT_SIZE="2.1132478632478633" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.6099476499757437" LOG_CI_START="0.03995322707036709" LOG_EFFECT_SIZE="0.3249504385230554" ORDER="168" O_E="0.0" SE="0.3348175455325164" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.1121027887964187" WEIGHT="9.07909766843539"/>
<DICH_DATA CI_END="1.9641012448162838" CI_START="0.968450524020787" EFFECT_SIZE="1.3791790600832838" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="41" LOG_CI_END="0.2931638708907155" LOG_CI_START="-0.013922561515458703" LOG_EFFECT_SIZE="0.13962065468762838" ORDER="166" O_E="0.0" SE="0.180384090497743" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.03253842010469794" WEIGHT="37.59767089247753"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.756529899137757" CI_END="4.857774356942502" CI_START="2.3250237491266756" DF="4" EFFECT_SIZE="3.360720272172304" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="32" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.6864373380091165" LOG_CI_START="0.36642739338166647" LOG_EFFECT_SIZE="0.5264323656953915" MODIFIED="2008-08-07 12:10:22 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.780425141552038" P_Z="1.1297927022407623E-10" STUDIES="5" TAU2="0.0" TOTAL_1="423" TOTAL_2="419" WEIGHT="100.00000000000003" Z="6.4484775825349825">
<NAME>Hepatitis C genotype 1 or 4</NAME>
<DICH_DATA CI_END="8.696240192738072" CI_START="0.6508611947558389" EFFECT_SIZE="2.3790849673202614" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9393315265865325" LOG_CI_START="-0.18651162092361814" LOG_EFFECT_SIZE="0.3764099528314572" ORDER="81" O_E="0.0" SE="0.6613258378609231" STUDY_ID="STD-ACTG-2004" TOTAL_1="51" TOTAL_2="52" VAR="0.43735186382245206" WEIGHT="9.25543793192238"/>
<DICH_DATA CI_END="7.468396440489801" CI_START="2.2830602988319395" EFFECT_SIZE="4.129261363636363" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="12" LOG_CI_END="0.8732273632871361" LOG_CI_START="0.35851738196949495" LOG_EFFECT_SIZE="0.6158723726283155" ORDER="82" O_E="0.0" SE="0.3023431908814812" STUDY_ID="STD-APRICOT-2004" TOTAL_1="176" TOTAL_2="171" VAR="0.09141140507239578" WEIGHT="37.92339466121691"/>
<DICH_DATA CI_END="5.602487886915732" CI_START="1.2415344435105296" EFFECT_SIZE="2.6373626373626373" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.748380926224262" LOG_CI_START="0.09395877255676284" LOG_EFFECT_SIZE="0.42116984939051244" ORDER="173" O_E="0.0" SE="0.3844108125061947" STUDY_ID="STD-Crespo-2007" TOTAL_1="39" TOTAL_2="40" VAR="0.14777167277167277" WEIGHT="21.531700108192723"/>
<DICH_DATA CI_END="20.665433292834965" CI_START="1.2401823802497258" EFFECT_SIZE="5.0625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.3152445155802002" LOG_CI_START="0.09348555686524979" LOG_EFFECT_SIZE="0.704365036222725" ORDER="171" O_E="0.0" SE="0.7176672601535452" STUDY_ID="STD-Laguno-2004" TOTAL_1="32" TOTAL_2="27" VAR="0.5150462962962963" WEIGHT="6.758817641213286"/>
<DICH_DATA CI_END="5.887619590758822" CI_START="1.2464597766334562" EFFECT_SIZE="2.709" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="8" LOG_CI_END="0.7699397417215225" LOG_CI_START="0.09567826834481417" LOG_EFFECT_SIZE="0.4328090050331682" ORDER="172" O_E="0.0" SE="0.3960645271096005" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="125" TOTAL_2="129" VAR="0.15686710963455147" WEIGHT="24.530649657454717"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.89488641604747" CI_END="2.1195566477213683" CI_START="1.3584401449044206" DF="4" EFFECT_SIZE="1.696847323616283" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="72" I2="76.32419714760182" ID="CMP-001.01.03" LOG_CI_END="0.32624502810595885" LOG_CI_START="0.13304050744997076" LOG_EFFECT_SIZE="0.22964276777796477" MODIFIED="2008-08-07 12:51:58 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0020259924441755617" P_Z="3.174039087578722E-6" STUDIES="5" TAU2="0.0" TOTAL_1="230" TOTAL_2="216" WEIGHT="100.00000000000001" Z="4.659223838310911">
<NAME>Hepatitis C genotype 2 or 3</NAME>
<DICH_DATA CI_END="4.78976332523945" CI_START="1.0104883417716761" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6803140543160356" LOG_CI_START="0.004531307328376933" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="80" O_E="0.0" SE="0.3969581307590986" STUDY_ID="STD-ACTG-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.1575757575757576" WEIGHT="6.733404601711767"/>
<DICH_DATA CI_END="4.775163716146141" CI_START="1.9747110203423937" EFFECT_SIZE="3.070760233918129" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="18" LOG_CI_END="0.6789882659302378" LOG_CI_START="0.29550354985956856" LOG_EFFECT_SIZE="0.4872459078949032" MODIFIED="2008-08-06 16:36:40 +0200" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.2252608204998707" STUDY_ID="STD-APRICOT-2004" TOTAL_1="95" TOTAL_2="89" VAR="0.05074243725227497" WEIGHT="25.030699715058958"/>
<DICH_DATA CI_END="2.926823758141685" CI_START="0.9490758608374356" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.46639657170916066" LOG_CI_START="-0.022699072476447868" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="177" O_E="0.0" SE="0.28729720245711154" STUDY_ID="STD-Crespo-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.08253968253968252" WEIGHT="12.12012828308118"/>
<DICH_DATA CI_END="2.246182343045897" CI_START="0.5662839166892418" EFFECT_SIZE="1.1278195488721805" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.35144500898877373" LOG_CI_START="-0.24696577281158277" LOG_EFFECT_SIZE="0.052239618088595466" ORDER="176" O_E="0.0" SE="0.3515094554106728" STUDY_ID="STD-Laguno-2004" TOTAL_1="19" TOTAL_2="15" VAR="0.12355889724310777" WEIGHT="10.535797788560764"/>
<DICH_DATA CI_END="1.4401664774236376" CI_START="0.7049246897278871" EFFECT_SIZE="1.0075757575757576" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="33" LOG_CI_END="0.15841269768377692" LOG_CI_START="-0.15185727816130504" LOG_EFFECT_SIZE="0.003277709761235921" ORDER="175" O_E="0.0" SE="0.18225411967255162" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="80" TOTAL_2="76" VAR="0.03321656413761677" WEIGHT="45.579969611587345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8720705168546133" CI_END="4.365655244559171" CI_START="2.3295371595671432" DF="1" EFFECT_SIZE="3.1890368637034876" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="42" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.6400494365271966" LOG_CI_START="0.36726964247955873" LOG_EFFECT_SIZE="0.5036595395033777" MODIFIED="2009-05-27 19:42:21 +0200" MODIFIED_BY="Emanuela Marchesini" NO="4" P_CHI2="0.35038283521570257" P_Z="4.562243271013439E-13" STUDIES="2" TAU2="0.0" TOTAL_1="356" TOTAL_2="356" WEIGHT="100.0" Z="7.237739593895679">
<NAME>Peginterferon 2a</NAME>
<DICH_DATA CI_END="4.885487564691511" CI_START="1.0678711616618684" EFFECT_SIZE="2.284090909090909" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6889079121875934" LOG_CI_START="0.028518858353047124" LOG_EFFECT_SIZE="0.35871338527032026" ORDER="121" O_E="0.0" SE="0.3879157992009504" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.15047866726971204" WEIGHT="18.90504683716202"/>
<DICH_DATA CI_END="4.804495417566599" CI_START="2.4060799304196143" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="34" LOG_CI_END="0.6816477834981504" LOG_CI_START="0.3813100505863598" LOG_EFFECT_SIZE="0.5314789170422551" MODIFIED="2009-05-27 19:42:21 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="120" O_E="0.0" SE="0.17641987100814083" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.03112397088652905" WEIGHT="81.09495316283798"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1104908600648846" CI_END="2.188537936774856" CI_START="1.3039637644172934" DF="2" EFFECT_SIZE="1.6893117434644789" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="66" I2="5.235315734155215" ID="CMP-001.01.05" LOG_CI_END="0.3401540792055563" LOG_CI_START="0.1152655230429329" LOG_EFFECT_SIZE="0.22770980112424455" MODIFIED="2008-09-22 16:52:11 +0200" MODIFIED_BY="dimitrinka nikolova" NO="5" P_CHI2="0.3481071624186497" P_Z="7.214345864658609E-5" STUDIES="3" TAU2="0.0" TOTAL_1="317" TOTAL_2="311" WEIGHT="100.00000000000001" Z="3.96910377962997">
<NAME>Peginterferon 2b</NAME>
<DICH_DATA CI_END="3.385527380489774" CI_START="1.298729642821236" EFFECT_SIZE="2.096875" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5296263305090261" LOG_CI_START="0.11351875318914606" LOG_EFFECT_SIZE="0.32157254184908607" ORDER="124" O_E="0.0" SE="0.2444236506834247" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.05974292101341282" WEIGHT="23.853640334089363"/>
<DICH_DATA CI_END="4.073311749878888" CI_START="1.0963601132799232" EFFECT_SIZE="2.1132478632478633" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.6099476499757437" LOG_CI_START="0.03995322707036709" LOG_EFFECT_SIZE="0.3249504385230554" ORDER="122" O_E="0.0" SE="0.3348175455325164" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.1121027887964187" WEIGHT="14.811227465337858"/>
<DICH_DATA CI_END="2.0274215431861795" CI_START="1.006415195796364" EFFECT_SIZE="1.4284354550862581" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="41" LOG_CI_END="0.30694405695442223" LOG_CI_START="0.0027771855343082306" LOG_EFFECT_SIZE="0.15486062124436523" ORDER="123" O_E="0.0" SE="0.17866912592247133" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.031922656557899914" WEIGHT="61.335132200572794"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="109.91903101417279" CI_END="2.320530105917439" CI_START="1.9136298359684403" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1072815772806957" ESTIMABLE="YES" EVENTS_1="885" EVENTS_2="411" I2="82.71454922346418" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.36558720720839993" LOG_CI_START="0.28185793357474787" LOG_EFFECT_SIZE="0.3237225703915739" METHOD="MH" MODIFIED="2009-11-09 22:49:59 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="7.993605777301127E-15" P_Q="0.0" P_Z="6.955461320091673E-52" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1999" TOTAL_2="1972" WEIGHT="500.0" Z="15.15562124010135">
<NAME>End of treatment virological response</NAME>
<GROUP_LABEL_1>Peginterferon ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Interferon ribavirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN ribavirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.849113462394655" CI_END="2.7180545273991026" CI_START="1.9131661743957655" DF="4" EFFECT_SIZE="2.280370579967921" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="129" I2="76.25987854537537" ID="CMP-001.02.01" LOG_CI_END="0.4342581649465149" LOG_CI_START="0.28175269375379935" LOG_EFFECT_SIZE="0.35800542935015717" MODIFIED="2008-08-06 16:08:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002067872794687009" P_Z="3.513451243199011E-20" STUDIES="5" TAU2="0.0" TOTAL_1="673" TOTAL_2="667" WEIGHT="100.0" Z="9.202000981452294">
<NAME>All patients</NAME>
<DICH_DATA CI_END="6.982562575468484" CI_START="1.6811034996623482" EFFECT_SIZE="3.4261363636363638" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" LOG_CI_END="0.8440148363972306" LOG_CI_START="0.2255944522547724" LOG_EFFECT_SIZE="0.5348046443260015" ORDER="149" O_E="0.0" SE="0.36326319487555236" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.13196014875119355" WEIGHT="6.1156411011981024"/>
<DICH_DATA CI_END="4.631872915590351" CI_START="2.478568286888322" EFFECT_SIZE="3.3882758620689657" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="40" LOG_CI_END="0.665756635172102" LOG_CI_START="0.39420088862759173" LOG_EFFECT_SIZE="0.5299787618998469" MODIFIED="2008-08-06 16:08:02 +0200" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.1595131897428701" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.025444457701944877" WEIGHT="30.863070768986606"/>
<DICH_DATA CI_END="2.216326808001701" CI_START="1.0493150160002103" EFFECT_SIZE="1.525" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.34563379957943813" LOG_CI_START="0.02090588778617114" LOG_EFFECT_SIZE="0.1832698436828046" ORDER="152" O_E="0.0" SE="0.19074678281645266" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.03638433515482696" WEIGHT="18.333138988565313"/>
<DICH_DATA CI_END="2.9003491993978856" CI_START="1.0169995432803114" EFFECT_SIZE="1.717455621301775" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="13" LOG_CI_END="0.46245028970641644" LOG_CI_START="0.007320757887459368" LOG_EFFECT_SIZE="0.2348855237969379" ORDER="151" O_E="0.0" SE="0.26734533991797266" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.07147353077585636" WEIGHT="10.961823367753569"/>
<DICH_DATA CI_END="2.2788849839529703" CI_START="1.1980369199768908" EFFECT_SIZE="1.6523281596452328" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="44" LOG_CI_END="0.35772240675341144" LOG_CI_START="0.07847020193907767" LOG_EFFECT_SIZE="0.2180963043462445" ORDER="153" O_E="0.0" SE="0.16403412742864723" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.026907194961277678" WEIGHT="33.72632577349642"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.197980194591871" CI_END="5.468484355748328" CI_START="2.816514607395084" DF="4" EFFECT_SIZE="3.9245466067148014" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="37" I2="23.047032688548605" ID="CMP-001.02.02" LOG_CI_END="0.7378669740217513" LOG_CI_START="0.4497120079749305" LOG_EFFECT_SIZE="0.5937894909983409" MODIFIED="2008-08-07 12:10:46 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2675800787636944" P_Z="6.603228818189009E-16" STUDIES="5" TAU2="0.0" TOTAL_1="423" TOTAL_2="419" WEIGHT="100.00000000000001" Z="8.077639838877657">
<NAME>Hepatitis C genotype 1 or 4</NAME>
<DICH_DATA CI_END="16.55568851805348" CI_START="1.5698533960900392" EFFECT_SIZE="5.098039215686274" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2189472469046632" LOG_CI_START="0.1958590968410999" LOG_EFFECT_SIZE="0.7074031718728816" ORDER="84" O_E="0.0" SE="0.600967043715357" STUDY_ID="STD-ACTG-2004" TOTAL_1="51" TOTAL_2="52" VAR="0.36116138763197586" WEIGHT="7.994845600415181"/>
<DICH_DATA CI_END="8.726700952502407" CI_START="2.873291526971567" EFFECT_SIZE="5.00743006993007" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="13" LOG_CI_END="0.9408500937731515" LOG_CI_START="0.45837969217083585" LOG_EFFECT_SIZE="0.6996148929719936" ORDER="85" O_E="0.0" SE="0.2834055021682057" STUDY_ID="STD-APRICOT-2004" TOTAL_1="176" TOTAL_2="171" VAR="0.08031867865921284" WEIGHT="35.48807318709844"/>
<DICH_DATA CI_END="3.804826165778094" CI_START="1.1059002095175627" EFFECT_SIZE="2.051282051282051" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5803348195907125" LOG_CI_START="0.04371594034017615" LOG_EFFECT_SIZE="0.3120253799654443" ORDER="157" O_E="0.0" SE="0.3152125859780577" STUDY_ID="STD-Crespo-2007" TOTAL_1="39" TOTAL_2="40" VAR="0.0993589743589744" WEIGHT="26.570112332975743"/>
<DICH_DATA CI_END="11.502779034493471" CI_START="1.1621682049540192" EFFECT_SIZE="3.65625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.0608027771831656" LOG_CI_START="0.06526898966934577" LOG_EFFECT_SIZE="0.5630358834262557" ORDER="154" O_E="0.0" SE="0.5847814747573432" STUDY_ID="STD-Laguno-2004" TOTAL_1="32" TOTAL_2="27" VAR="0.3419693732193732" WEIGHT="8.757398171807392"/>
<DICH_DATA CI_END="8.60589748509054" CI_START="1.9800821505859159" EFFECT_SIZE="4.128" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="8" LOG_CI_END="0.9347961683878724" LOG_CI_START="0.2966832088504375" LOG_EFFECT_SIZE="0.615739688619155" ORDER="158" O_E="0.0" SE="0.37483071114238203" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="125" TOTAL_2="129" VAR="0.14049806201550386" WEIGHT="21.18957070770325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.005804486871408" CI_END="1.363412953611334" CI_START="0.9907043973465585" DF="4" EFFECT_SIZE="1.162213065036703" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="116" I2="0.1449019014890023" ID="CMP-001.02.03" LOG_CI_END="0.13462741585812363" LOG_CI_START="-0.004055909341044757" LOG_EFFECT_SIZE="0.06528575325853941" MODIFIED="2008-08-07 12:10:36 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.40522107853045153" P_Z="0.06499065003550715" STUDIES="5" TAU2="0.0" TOTAL_1="230" TOTAL_2="219" WEIGHT="99.99999999999999" Z="1.8453224265648491">
<NAME>Hepatitis C genotype 2 or 3</NAME>
<DICH_DATA CI_END="5.127199093895742" CI_START="1.1234203888937426" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.709880181825325" LOG_CI_START="0.050542301597886995" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="83" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-ACTG-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.15000000000000002" WEIGHT="4.201308373887106"/>
<DICH_DATA CI_END="1.4331593682508825" CI_START="0.8959064003848074" EFFECT_SIZE="1.13312693498452" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="51" LOG_CI_END="0.1562944869106416" LOG_CI_START="-0.047737360784026066" LOG_EFFECT_SIZE="0.054278563063307764" ORDER="161" O_E="0.0" SE="0.1198493173097825" STUDY_ID="STD-APRICOT-2004" TOTAL_1="95" TOTAL_2="90" VAR="0.014363858859620932" WEIGHT="44.01154393834169"/>
<DICH_DATA CI_END="1.680437618558504" CI_START="0.7772513746151413" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.2254223951639231" LOG_CI_START="-0.10943850120854968" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="160" O_E="0.0" SE="0.1966989481173608" STUDY_ID="STD-Crespo-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.03869047619047619" WEIGHT="11.763663446883898"/>
<DICH_DATA CI_END="1.642908627689459" CI_START="0.6411337076026911" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.21561341030436137" LOG_CI_START="-0.19305138948498318" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="159" O_E="0.0" SE="0.24005172631964522" STUDY_ID="STD-Laguno-2004" TOTAL_1="19" TOTAL_2="15" VAR="0.05762483130904185" WEIGHT="9.391159894571178"/>
<DICH_DATA CI_END="1.4990226410772483" CI_START="0.7829175350331696" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="36" LOG_CI_END="0.17580819243510762" LOG_CI_START="-0.10628397991668379" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="162" O_E="0.0" SE="0.1657023384182159" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="80" TOTAL_2="78" VAR="0.027457264957264953" WEIGHT="30.63232434631612"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.845711735130999E-4" CI_END="4.5197021002020445" CI_START="2.549478587277058" DF="1" EFFECT_SIZE="3.39453733597618" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="48" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.6551098108065145" LOG_CI_START="0.4064513687386881" LOG_EFFECT_SIZE="0.5307805897726012" MODIFIED="2008-09-22 16:51:48 +0200" MODIFIED_BY="dimitrinka nikolova" NO="4" P_CHI2="0.9776540186913826" P_Z="5.890944132968616E-17" STUDIES="2" TAU2="0.0" TOTAL_1="356" TOTAL_2="356" WEIGHT="100.0" Z="8.367388060474237">
<NAME>Peginterferon 2a</NAME>
<DICH_DATA CI_END="6.982562575468484" CI_START="1.6811034996623482" EFFECT_SIZE="3.4261363636363638" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" LOG_CI_END="0.8440148363972306" LOG_CI_START="0.2255944522547724" LOG_EFFECT_SIZE="0.5348046443260015" ORDER="116" O_E="0.0" SE="0.36326319487555236" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.13196014875119355" WEIGHT="16.538275109926253"/>
<DICH_DATA CI_END="4.631872915590351" CI_START="2.478568286888322" EFFECT_SIZE="3.3882758620689657" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="40" LOG_CI_END="0.665756635172102" LOG_CI_START="0.39420088862759173" LOG_EFFECT_SIZE="0.5299787618998469" ORDER="115" O_E="0.0" SE="0.1595131897428701" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.025444457701944877" WEIGHT="83.46172489007375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1648264108307621" CI_END="2.033894349406526" CI_START="1.3008934482930758" DF="2" EFFECT_SIZE="1.6266160683035373" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="81" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.30832838975612464" LOG_CI_START="0.1142417264513569" LOG_EFFECT_SIZE="0.21128505810374076" MODIFIED="2008-09-22 16:51:08 +0200" MODIFIED_BY="dimitrinka nikolova" NO="5" P_CHI2="0.9208913923520634" P_Z="1.978704159941084E-5" STUDIES="3" TAU2="0.0" TOTAL_1="317" TOTAL_2="311" WEIGHT="100.0" Z="4.267280371598951">
<NAME>Peginterferon 2b</NAME>
<DICH_DATA CI_END="2.216326808001701" CI_START="1.0493150160002103" EFFECT_SIZE="1.525" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.34563379957943813" LOG_CI_START="0.02090588778617114" LOG_EFFECT_SIZE="0.1832698436828046" ORDER="118" O_E="0.0" SE="0.19074678281645266" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.03638433515482696" WEIGHT="29.090390775259202"/>
<DICH_DATA CI_END="2.9003491993978856" CI_START="1.0169995432803114" EFFECT_SIZE="1.717455621301775" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="13" LOG_CI_END="0.46245028970641644" LOG_CI_START="0.007320757887459368" LOG_EFFECT_SIZE="0.2348855237969379" ORDER="119" O_E="0.0" SE="0.26734533991797266" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.07147353077585636" WEIGHT="17.393842133429107"/>
<DICH_DATA CI_END="2.2788849839529703" CI_START="1.1980369199768908" EFFECT_SIZE="1.6523281596452328" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="44" LOG_CI_END="0.35772240675341144" LOG_CI_START="0.07847020193907767" LOG_EFFECT_SIZE="0.2180963043462445" ORDER="117" O_E="0.0" SE="0.16403412742864723" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.026907194961277678" WEIGHT="53.515767091311695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1034402869553044" CI_END="3.298919240081771" CI_START="0.4918050770309901" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2737445705428663" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="4.917671663740572" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.518371683833869" LOG_CI_START="-0.30820699223991577" LOG_EFFECT_SIZE="0.10508234579697665" METHOD="MH" MODIFIED="2009-09-23 11:33:15 +0200" MODIFIED_BY="Alfonso Iorio" NO="3" P_CHI2="0.3493364994825804" P_Q="0.0" P_Z="0.6182461183951846" Q="0.0" RANDOM="NO" SCALE="108.48019519113545" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="607" TOTAL_2="600" WEIGHT="100.0" Z="0.4983375911688129">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Peginterferon ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Interferon ribavirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pegIFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IFN ribavirin</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.88428005116745" CI_START="0.3000432278686131" EFFECT_SIZE="1.328735632183908" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7696933339709209" LOG_CI_START="-0.5228161710391374" LOG_EFFECT_SIZE="0.12343858146589173" MODIFIED="2008-08-06 16:18:56 +0200" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.7592264812681441" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.5764248498588075" WEIGHT="40.20230216094993"/>
<DICH_DATA CI_END="4.147653110424931" CI_START="0.009962796817413652" EFFECT_SIZE="0.20327868852459016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6178024269532576" LOG_CI_START="-2.001618726650322" LOG_EFFECT_SIZE="-0.691908149848532" MODIFIED="2008-08-06 15:28:58 +0200" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="1.5386609519705714" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="2.367477525118985" WEIGHT="33.17225282736638"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-06 15:29:02 +0200" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.0" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.863723519818327" CI_START="0.4953889201436921" EFFECT_SIZE="2.524390243902439" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.109366697207577" LOG_CI_START="-0.305053711061175" LOG_EFFECT_SIZE="0.40215649307320106" ORDER="182" O_E="0.0" SE="0.8308375493110046" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.690291033345116" WEIGHT="26.625445011683695"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.820393283501085" CI_END="3.0624484590317635" CI_START="1.9237044765144895" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4271888698109803" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="82" I2="65.987911155712" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.4860687882635417" LOG_CI_START="0.28413835560367656" LOG_EFFECT_SIZE="0.3851035719336091" METHOD="MH" MODIFIED="2009-09-23 11:33:27 +0200" MODIFIED_BY="Alfonso Iorio" NO="4" P_CHI2="0.03177677361521347" P_Q="0.0" P_Z="7.677393458114061E-14" Q="0.0" RANDOM="NO" SCALE="4.826114826667677" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="730" TOTAL_2="735" WEIGHT="200.0" Z="7.4757343047838924">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>PegIFN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN ribavirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.366825734701127" CI_END="3.4003941686471926" CI_START="1.7166217456015231" DF="1" EFFECT_SIZE="2.4160278503188626" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="41" I2="77.10007083512707" ID="CMP-001.04.01" LOG_CI_END="0.5315292627323317" LOG_CI_START="0.2346746097238767" LOG_EFFECT_SIZE="0.38310193622810423" MODIFIED="2008-08-06 16:19:10 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03664541189779169" P_Z="4.2187568932525646E-7" STUDIES="2" TAU2="0.0" TOTAL_1="495" TOTAL_2="496" WEIGHT="100.00000000000001" Z="5.058812383804936">
<NAME>All patients</NAME>
<DICH_DATA CI_END="4.6748611812022265" CI_START="2.015266119271179" EFFECT_SIZE="3.0693793103448277" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="25" LOG_CI_END="0.669768719137313" LOG_CI_START="0.30433240357875924" LOG_EFFECT_SIZE="0.48705056135803604" MODIFIED="2008-08-06 16:19:10 +0200" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.21465910069803068" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.046078529512487275" WEIGHT="61.13235041300665"/>
<DICH_DATA CI_END="2.566380682946681" CI_START="0.7511337694836322" EFFECT_SIZE="1.3884146341463415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.4093210776977276" LOG_CI_START="-0.12428271256283781" LOG_EFFECT_SIZE="0.1425191825674449" MODIFIED="2008-08-06 15:45:53 +0200" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.3134415077804175" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.09824557879966152" WEIGHT="38.867649586993366"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.4479391964481625" CI_END="3.3419567839304847" CI_START="1.77916772029554" DF="1" EFFECT_SIZE="2.4384219554030873" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="41" I2="77.51767828124684" ID="CMP-001.04.02" LOG_CI_END="0.5240008295723723" LOG_CI_START="0.25021689050408963" LOG_EFFECT_SIZE="0.387108860038231" MODIFIED="2008-08-06 15:44:35 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.034943431393636204" P_Z="2.9823713293554806E-8" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="239" WEIGHT="100.0" Z="5.54246846146853">
<NAME>Patients with paired biopsies</NAME>
<DICH_DATA CI_END="4.482358057730215" CI_START="2.085148293853306" EFFECT_SIZE="3.057185185185185" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="25" LOG_CI_END="0.651506545703143" LOG_CI_START="0.3191369470373485" LOG_EFFECT_SIZE="0.4853217463702457" ORDER="185" O_E="0.0" SE="0.19523554751233546" STUDY_ID="STD-APRICOT-2004" TOTAL_1="135" TOTAL_2="134" VAR="0.0381169190124414" WEIGHT="61.64932837317057"/>
<DICH_DATA CI_END="2.585927850574132" CI_START="0.8060604096271345" EFFECT_SIZE="1.44375" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.412616403554953" LOG_CI_START="-0.09363240908251386" LOG_EFFECT_SIZE="0.15949199723621957" ORDER="186" O_E="0.0" SE="0.2973730585152864" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="100" TOTAL_2="105" VAR="0.08843073593073594" WEIGHT="38.35067162682943"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.985671868529813" CI_END="0.9580659083266745" CI_START="0.7083583410260259" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8238045747723642" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="241" I2="55.48468652623459" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.018604613428752324" LOG_CI_START="-0.14974698784689314" LOG_EFFECT_SIZE="-0.0841758006378227" METHOD="MH" MODIFIED="2009-10-29 13:39:26 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" P_CHI2="0.061458681052733" P_Q="0.0" P_Z="0.011867242894472448" Q="0.0" RANDOM="NO" SCALE="3.0267944574909302" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="673" TOTAL_2="667" WEIGHT="100.0" Z="2.516067569341409">
<NAME>Losses to follow-up</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN ribavirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PegIFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IFN ribavirin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5451302172487145" CI_START="0.40490368301407487" EFFECT_SIZE="1.0151515151515151" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4057100071780157" LOG_CI_START="-0.3926482728601002" LOG_EFFECT_SIZE="0.006530867158957755" ORDER="188" O_E="0.0" SE="0.46895960563161143" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.21992311171415652" WEIGHT="3.282477758375893"/>
<DICH_DATA CI_END="0.8282151387742197" CI_START="0.5045167162633838" EFFECT_SIZE="0.6464119291705499" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="111" LOG_CI_END="-0.08185683538155504" LOG_CI_START="-0.2971244396140393" LOG_EFFECT_SIZE="-0.18949063749779718" MODIFIED="2008-08-06 16:16:37 +0200" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.1264492563179878" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.01598941442337218" WEIGHT="45.96866839575142"/>
<DICH_DATA CI_END="1.505496484913865" CI_START="0.35028484821731243" EFFECT_SIZE="0.7261904761904762" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.17767974584393323" LOG_CI_START="-0.45557864794616243" LOG_EFFECT_SIZE="-0.13894945105111464" ORDER="190" O_E="0.0" SE="0.3719791151919069" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.13836846213895396" WEIGHT="5.740020272441691"/>
<DICH_DATA CI_END="2.30214063031179" CI_START="0.8016743250546072" EFFECT_SIZE="1.3585164835164836" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.3621318497468246" LOG_CI_START="-0.09600202517854009" LOG_EFFECT_SIZE="0.13306491228414222" ORDER="189" O_E="0.0" SE="0.26911010593041473" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.07242024911387904" WEIGHT="6.336176763895284"/>
<DICH_DATA CI_END="1.1747545343175516" CI_START="0.7606685767717651" EFFECT_SIZE="0.9453035806953815" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="94" LOG_CI_END="0.06994712998806582" LOG_CI_START="-0.11880452408479887" LOG_EFFECT_SIZE="-0.024428697048366563" ORDER="191" O_E="0.0" SE="0.11087365593815714" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.012292967581092846" WEIGHT="38.67265680953571"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.291151727768277" CI_END="1.2415438906398382" CI_START="1.0604489293902946" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1474292525555017" ESTIMABLE="YES" EVENTS_1="678" EVENTS_2="581" I2="8.443783377177429" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.09396207719365017" LOG_CI_START="0.025489757984071135" LOG_EFFECT_SIZE="0.05972591758886063" METHOD="MH" MODIFIED="2009-09-23 11:33:40 +0200" MODIFIED_BY="Alfonso Iorio" NO="6" P_CHI2="0.3585461811920402" P_Q="0.0" P_Z="6.28030472849963E-4" Q="0.0" RANDOM="NO" SCALE="30.673379120173312" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2019" TOTAL_2="2001" WEIGHT="300.0" Z="3.419210821806012">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN ribavirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PegIFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IFNribavirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7025203707994057" CI_END="2.139612949372799" CI_START="1.1552767785181453" DF="4" EFFECT_SIZE="1.5722102771026256" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="56" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.3303352176694799" LOG_CI_START="0.06268604395367533" LOG_EFFECT_SIZE="0.19651063081157763" MODIFIED="2008-08-07 12:11:50 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7902597700755458" P_Z="0.0040014259600567315" STUDIES="5" TAU2="0.0" TOTAL_1="673" TOTAL_2="667" WEIGHT="99.99999999999999" Z="2.8780493032935976">
<NAME>Anaemia</NAME>
<DICH_DATA CI_END="21.85550755410796" CI_START="0.18860831232825215" EFFECT_SIZE="2.0303030303030303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.339560896636187" LOG_CI_START="-0.724439170990309" LOG_EFFECT_SIZE="0.30756086282293893" ORDER="198" O_E="0.0" SE="1.2124038566889155" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="1.4699231117141565" WEIGHT="1.7427744474541706"/>
<DICH_DATA CI_END="2.1239526595281206" CI_START="0.9542425480279924" EFFECT_SIZE="1.4236453201970443" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" LOG_CI_END="0.32714483259077215" LOG_CI_START="-0.02034122290410231" LOG_EFFECT_SIZE="0.1534018048433349" MODIFIED="2008-08-06 16:19:48 +0200" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.20411502908140514" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.04166294509690286" WEIGHT="61.565352105007534"/>
<DICH_DATA CI_END="28.50499069045623" CI_START="0.3263463616255301" EFFECT_SIZE="3.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4549209035024329" LOG_CI_START="-0.4863212248088613" LOG_EFFECT_SIZE="0.4842998393467858" ORDER="200" O_E="0.0" SE="1.1402952354735663" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="1.3002732240437158" WEIGHT="1.7414650752171654"/>
<DICH_DATA CI_END="2.608954121872401" CI_START="0.6709709955046551" EFFECT_SIZE="1.323076923076923" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.416466442153942" LOG_CI_START="-0.17329625295251774" LOG_EFFECT_SIZE="0.12158509460071214" ORDER="201" O_E="0.0" SE="0.34642952647795827" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.12001341681574239" WEIGHT="19.22333026888843"/>
<DICH_DATA CI_END="4.810720643357516" CI_START="1.04664114363238" EFFECT_SIZE="2.2439024390243905" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6822101383262107" LOG_CI_START="0.019797802925428952" LOG_EFFECT_SIZE="0.35100397062581984" ORDER="199" O_E="0.0" SE="0.38910428480836234" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.15140214445622716" WEIGHT="15.72707810343269"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4023992671609005" CI_END="1.2599499351125174" CI_START="1.0692607264049574" DF="4" EFFECT_SIZE="1.1606959045556633" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="366" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.10035328850141295" LOG_CI_START="0.029083615622903253" LOG_EFFECT_SIZE="0.06471845206215812" MODIFIED="2008-08-07 12:15:01 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6621937852480145" P_Z="3.7141725167019984E-4" STUDIES="5" TAU2="0.0" TOTAL_1="673" TOTAL_2="667" WEIGHT="100.0" Z="3.5596020033160647">
<NAME>Flu-like symptoms</NAME>
<DICH_DATA CI_END="1.3576689061169107" CI_START="0.6698281120336684" EFFECT_SIZE="0.9536271808999082" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.13279387172779955" LOG_CI_START="-0.17403662949711365" LOG_EFFECT_SIZE="-0.020621378884657038" ORDER="86" O_E="0.0" SE="0.18023375525499052" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.032484206533315824" WEIGHT="8.904324404868053"/>
<DICH_DATA CI_END="1.5483473723670447" CI_START="1.0301690074388554" EFFECT_SIZE="1.2629566404916355" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="101" LOG_CI_END="0.18986840142306416" LOG_CI_START="0.012908480022571056" LOG_EFFECT_SIZE="0.1013884407228176" ORDER="87" O_E="0.0" SE="0.10394713379638801" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.010805006624484189" WEIGHT="27.506513574964465"/>
<DICH_DATA CI_END="1.2834186948738817" CI_START="0.9422114709741216" EFFECT_SIZE="1.0996598639455781" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" LOG_CI_END="0.10836836113674655" LOG_CI_START="-0.025851612737949056" LOG_EFFECT_SIZE="0.04125837419939874" ORDER="88" O_E="0.0" SE="0.07884147705358215" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.00621597850399052" WEIGHT="13.211639037981262"/>
<DICH_DATA CI_END="1.4531342783151122" CI_START="0.9723893263086067" EFFECT_SIZE="1.1887019230769231" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="32" LOG_CI_END="0.16230574756493155" LOG_CI_START="-0.012159816952020541" LOG_EFFECT_SIZE="0.07507296530645549" ORDER="89" O_E="0.0" SE="0.10248193621573025" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.010502547250525004" WEIGHT="9.52411117244289"/>
<DICH_DATA CI_END="1.2741554453482327" CI_START="1.0382777646279127" EFFECT_SIZE="1.1501857535131643" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="151" LOG_CI_END="0.10522241460749318" LOG_CI_START="0.016313553423592697" LOG_EFFECT_SIZE="0.06076798401554295" ORDER="90" O_E="0.0" SE="0.05222550516538392" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.002727503389779543" WEIGHT="40.853411809743335"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.170253971808242" CI_END="1.1690669999970398" CI_START="0.799241933664977" DF="4" EFFECT_SIZE="0.9666267995775556" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="159" I2="4.082580412588606" ID="CMP-001.06.03" LOG_CI_END="0.06783940157687947" LOG_CI_START="-0.097321738143503" LOG_EFFECT_SIZE="-0.01474116828331174" MODIFIED="2008-08-07 12:15:24 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3834546031005628" P_Z="0.7264390354061993" STUDIES="5" TAU2="0.0" TOTAL_1="673" TOTAL_2="667" WEIGHT="100.0" Z="0.3498663060118079">
<NAME>Depression</NAME>
<DICH_DATA CI_END="2.3099783936659533" CI_START="0.3415622947185122" EFFECT_SIZE="0.8882575757575758" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.36360791774689116" LOG_CI_START="-0.46653007738434904" LOG_EFFECT_SIZE="-0.05146107981872897" ORDER="91" O_E="0.0" SE="0.4876271675894395" STUDY_ID="STD-ACTG-2004" TOTAL_1="66" TOTAL_2="67" VAR="0.23778025457129937" WEIGHT="4.9381792877950375"/>
<DICH_DATA CI_END="1.5813433443258869" CI_START="0.8856064099683033" EFFECT_SIZE="1.183405172413793" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="64" LOG_CI_END="0.19902617502844658" LOG_CI_START="-0.05275924871945473" LOG_EFFECT_SIZE="0.07313346315449593" ORDER="92" O_E="0.0" SE="0.14790000426746577" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.02187441126231639" WEIGHT="39.87346524943835"/>
<DICH_DATA CI_END="2.092159852863746" CI_START="0.40017257708774373" EFFECT_SIZE="0.915" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32059486402143655" LOG_CI_START="-0.39775267588854" LOG_EFFECT_SIZE="-0.038578905933551705" ORDER="93" O_E="0.0" SE="0.42196090082079124" STUDY_ID="STD-Crespo-2007" TOTAL_1="60" TOTAL_2="61" VAR="0.17805100182149364" WEIGHT="6.168086450758265"/>
<DICH_DATA CI_END="1.133719372645923" CI_START="0.44986944432341675" EFFECT_SIZE="0.7141608391608392" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.05450556778983978" LOG_CI_START="-0.3469135036390196" LOG_EFFECT_SIZE="-0.14620396792458992" ORDER="94" O_E="0.0" SE="0.23579554961376237" STUDY_ID="STD-Laguno-2004" TOTAL_1="52" TOTAL_2="43" VAR="0.05559954121765627" WEIGHT="14.979143839644948"/>
<DICH_DATA CI_END="1.1873097257673653" CI_START="0.6007022074189468" EFFECT_SIZE="0.8445232815964523" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="55" LOG_CI_END="0.0745640253113594" LOG_CI_START="-0.22134077213437203" LOG_EFFECT_SIZE="-0.07338837341150634" ORDER="95" O_E="0.0" SE="0.1738159427719933" STUDY_ID="STD-RIBAVIC-2004" TOTAL_1="205" TOTAL_2="207" VAR="0.03021198196171685" WEIGHT="34.0411251723634"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-11-09 22:52:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Peginterferon plus ribavirin versus peginterferon</NAME>
<DICH_OUTCOME CHI2="2.3608439441646922" CI_END="2.3871320348536322" CI_START="1.6621249840586396" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.991911593263356" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="126" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.37787644096842105" LOG_CI_START="0.22066367759860034" LOG_EFFECT_SIZE="0.2992700592835107" METHOD="MH" MODIFIED="2009-11-09 22:50:53 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.7972906105615426" P_Q="0.0" P_Z="8.523767117983294E-14" Q="0.0" RANDOM="NO" SCALE="14.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="699" TOTAL_2="686" WEIGHT="300.0" Z="7.461970965640394">
<NAME>Sustained virological response</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>PegIFN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PegIFN</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN ribavirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1496785324369152" CI_END="2.6304350336139493" CI_START="1.568360869365931" DF="1" EFFECT_SIZE="2.031125642625137" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="64" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.42002758007676694" LOG_CI_START="0.19544599810760627" LOG_EFFECT_SIZE="0.3077367890921866" MODIFIED="2008-08-06 16:53:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6988429078787907" P_Z="7.814981041186578E-8" STUDIES="2" TAU2="0.0" TOTAL_1="359" TOTAL_2="355" WEIGHT="99.99999999999999" Z="5.371348959697941">
<NAME>All patients</NAME>
<DICH_DATA CI_END="2.6104566022349256" CI_START="1.5217496249997549" EFFECT_SIZE="1.993103448275862" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="58" LOG_CI_END="0.41671647763998737" LOG_CI_START="0.18234320340315857" LOG_EFFECT_SIZE="0.299529840521573" MODIFIED="2008-08-06 16:42:06 +0200" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.1376720214531316" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.018953585490991527" WEIGHT="90.45150465701562"/>
<DICH_DATA CI_END="5.791599137261576" CI_START="0.9873501857443351" EFFECT_SIZE="2.391304347826087" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.762798494746407" LOG_CI_START="-0.00552878779310505" LOG_EFFECT_SIZE="0.37863485347665093" MODIFIED="2008-08-06 16:53:09 +0200" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.45131924904509646" STUDY_ID="STD-ICOS-2005" TOTAL_1="69" TOTAL_2="66" VAR="0.20368906455862978" WEIGHT="9.548495342984362"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5150058405525014" CI_END="3.0516909518564654" CI_START="1.3250256970792549" DF="1" EFFECT_SIZE="2.010862732946749" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="27" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.48454055002355434" LOG_CI_START="0.12222430090792342" LOG_EFFECT_SIZE="0.3033824254657389" MODIFIED="2008-08-06 16:57:45 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4729799217491445" P_Z="0.0010295731485145216" STUDIES="2" TAU2="0.0" TOTAL_1="213" TOTAL_2="209" WEIGHT="100.00000000000001" Z="3.2823183001405325">
<NAME>Hepatitis C genotype 1 or 4</NAME>
<DICH_DATA CI_END="3.2733103993171966" CI_START="1.3638965796399378" EFFECT_SIZE="2.1129261363636362" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="24" LOG_CI_END="0.514987190251132" LOG_CI_START="0.13478144026581787" LOG_EFFECT_SIZE="0.32488431525847494" ORDER="212" O_E="0.0" SE="0.2233347395901893" STUDY_ID="STD-APRICOT-2004" TOTAL_1="176" TOTAL_2="175" VAR="0.04987840590781767" WEIGHT="88.50250099597186"/>
<DICH_DATA CI_END="5.082552402115779" CI_START="0.29535885393002337" EFFECT_SIZE="1.2252252252252251" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7060818649947596" LOG_CI_START="-0.5296500058276394" LOG_EFFECT_SIZE="0.08821592958356005" ORDER="213" O_E="0.0" SE="0.7258750178924909" STUDY_ID="STD-ICOS-2005" TOTAL_1="37" TOTAL_2="34" VAR="0.5268945416004239" WEIGHT="11.497499004028153"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4721709149182791" CI_END="2.6048990908632907" CI_START="1.396534086579633" DF="1" EFFECT_SIZE="1.9073097211755836" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="35" I2="32.073104429215654" ID="CMP-002.01.03" LOG_CI_END="0.41579090416910464" LOG_CI_START="0.14505154041853258" LOG_EFFECT_SIZE="0.2804212222938186" MODIFIED="2008-08-06 16:58:02 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.22500380598780645" P_Z="4.905007237460931E-5" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="122" WEIGHT="100.0" Z="4.060107762556">
<NAME>Hepatitis C genotype 2 or 3</NAME>
<DICH_DATA CI_END="2.404073792026194" CI_START="1.269094847613205" EFFECT_SIZE="1.7467105263157894" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="32" LOG_CI_END="0.38094779402035983" LOG_CI_START="0.10349408092507079" LOG_EFFECT_SIZE="0.24222093747271528" ORDER="215" O_E="0.0" SE="0.16297768449020278" STUDY_ID="STD-APRICOT-2004" TOTAL_1="95" TOTAL_2="90" VAR="0.026561725641788082" WEIGHT="91.63526752072343"/>
<DICH_DATA CI_END="11.918643405150743" CI_START="1.1280180124051964" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0762268262779175" LOG_CI_START="0.052316034599207514" LOG_EFFECT_SIZE="0.5642714304385625" ORDER="214" O_E="0.0" SE="0.601450267472236" STUDY_ID="STD-ICOS-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.3617424242424242" WEIGHT="8.364732479276565"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.060325677254971" CI_END="1.7144123073793702" CI_START="1.2958758414264655" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.49052524010066" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="200" I2="37.96776705798316" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.23411527574711904" LOG_CI_START="0.11256339353580667" LOG_EFFECT_SIZE="0.1733393346414629" METHOD="MH" MODIFIED="2009-11-09 22:51:26 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.1529422767696993" P_Q="0.0" P_Z="2.270407343939328E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="699" TOTAL_2="686" WEIGHT="300.0" Z="5.590022084738809">
<NAME>End of treatment</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>PegIFN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PegIFN</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN ribavirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.16997606006337634" CI_END="1.8730754782612804" CI_START="1.2526458282863673" DF="1" EFFECT_SIZE="1.5317637493783058" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="101" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.27255527824652115" LOG_CI_START="0.09782829640233429" LOG_EFFECT_SIZE="0.18519178732442773" MODIFIED="2008-08-06 16:46:49 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6801333558070569" P_Z="3.2571236545248216E-5" STUDIES="2" TAU2="0.0" TOTAL_1="359" TOTAL_2="355" WEIGHT="100.0" Z="4.154701575651988">
<NAME>All patients</NAME>
<DICH_DATA CI_END="1.8590784333641834" CI_START="1.2198172617401721" EFFECT_SIZE="1.5059003831417626" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="90" LOG_CI_END="0.2692977127728129" LOG_CI_START="0.08629477480415598" LOG_EFFECT_SIZE="0.17779624378848444" MODIFIED="2008-08-06 16:37:44 +0200" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.10749683164194183" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.011555568813055986" WEIGHT="88.91079170347626"/>
<DICH_DATA CI_END="3.3439686236111594" CI_START="0.9044865576283128" EFFECT_SIZE="1.7391304347826086" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.5242621938099021" LOG_CI_START="-0.04359788318916324" LOG_EFFECT_SIZE="0.2403321553103695" ORDER="222" O_E="0.0" SE="0.3335638201819666" STUDY_ID="STD-ICOS-2005" TOTAL_1="69" TOTAL_2="66" VAR="0.11126482213438736" WEIGHT="11.089208296523736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7063282441820209" CI_END="2.375855431071579" CI_START="1.2373672699443938" DF="1" EFFECT_SIZE="1.7145861741328725" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="42" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.3758200106365748" LOG_CI_START="0.09249862415324282" LOG_EFFECT_SIZE="0.2341593173949088" MODIFIED="2008-08-06 16:47:53 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4006659014107061" P_Z="0.0011963869328587055" STUDIES="2" TAU2="0.0" TOTAL_1="213" TOTAL_2="209" WEIGHT="100.00000000000001" Z="3.239740101762525">
<NAME>Hepatitis C genotype 1 or 4</NAME>
<DICH_DATA CI_END="2.5362470095213396" CI_START="1.278219300924261" EFFECT_SIZE="1.800522113022113" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="37" LOG_CI_END="0.4041915479668253" LOG_CI_START="0.10660537104512674" LOG_EFFECT_SIZE="0.255398459505976" MODIFIED="2008-08-06 16:39:00 +0200" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.17480359339913895" STUDY_ID="STD-APRICOT-2004" TOTAL_1="176" TOTAL_2="175" VAR="0.03055629626525149" WEIGHT="87.6850747315978"/>
<DICH_DATA CI_END="3.285198052997099" CI_START="0.37013088128386246" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5165615567667258" LOG_CI_START="-0.4316446787209558" LOG_EFFECT_SIZE="0.04245843902288498" MODIFIED="2008-08-06 16:47:53 +0200" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.5569810364220288" STUDY_ID="STD-ICOS-2005" TOTAL_1="37" TOTAL_2="34" VAR="0.3102278749337573" WEIGHT="12.314925268402218"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.925338601315829" CI_END="1.5827469138213712" CI_START="0.9974719896904981" DF="1" EFFECT_SIZE="1.2564814814814815" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="57" I2="65.81592299947104" ID="CMP-002.02.03" LOG_CI_END="0.19941147536889622" LOG_CI_START="-0.0010992910233215167" LOG_EFFECT_SIZE="0.09915609217278738" MODIFIED="2008-08-06 16:51:51 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08719908189138526" P_Z="0.052565522237418914" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="122" WEIGHT="100.0" Z="1.9384731603513539">
<NAME>Hepatitis C genotype 2 or 3</NAME>
<DICH_DATA CI_END="1.4331593682508825" CI_START="0.8959064003848074" EFFECT_SIZE="1.13312693498452" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="51" LOG_CI_END="0.1562944869106416" LOG_CI_START="-0.047737360784026066" LOG_EFFECT_SIZE="0.054278563063307764" MODIFIED="2008-08-06 16:40:13 +0200" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.1198493173097825" STUDY_ID="STD-APRICOT-2004" TOTAL_1="95" TOTAL_2="90" VAR="0.014363858859620932" WEIGHT="89.72222222222223"/>
<DICH_DATA CI_END="5.304751052921794" CI_START="1.0263336375503822" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7246650076757739" LOG_CI_START="0.011288562913414889" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-08-06 16:51:51 +0200" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.41904085492376286" STUDY_ID="STD-ICOS-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.17559523809523808" WEIGHT="10.277777777777779"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5080439421336087" CI_END="1.0505414077407265" CI_START="0.7058515927960691" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8611192286507232" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="129" I2="33.688934913582074" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.021413175065524318" LOG_CI_START="-0.15128660093816193" LOG_EFFECT_SIZE="-0.06493671293631878" METHOD="MH" MODIFIED="2009-11-09 22:51:57 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.21943819464546954" P_Q="0.0" P_Z="0.14050066324459373" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="359" TOTAL_2="355" WEIGHT="100.0" Z="1.4739291685807911">
<NAME>Losses to follow-up</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>PegIFN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PegIFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0377206213725623" CI_START="0.6124903021046069" EFFECT_SIZE="0.7972413793103448" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="90" LOG_CI_END="0.016080447031151267" LOG_CI_START="-0.21290078333208062" LOG_EFFECT_SIZE="-0.09841016815046467" MODIFIED="2008-08-06 16:43:05 +0200" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.13450470819073318" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.018091516525474288" WEIGHT="69.33854745041364"/>
<DICH_DATA CI_END="1.330305085105021" CI_START="0.7601108605326089" EFFECT_SIZE="1.0055741360089185" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="39" LOG_CI_END="0.12395125118017318" LOG_CI_START="-0.11912306218447391" LOG_EFFECT_SIZE="0.0024140944978496117" ORDER="82" O_E="0.0" SE="0.1427830549076504" STUDY_ID="STD-ICOS-2005" TOTAL_1="69" TOTAL_2="66" VAR="0.020387000768761106" WEIGHT="30.661452549586365"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.003544298402712" CI_END="1.057066878777124" CI_START="0.6000555058060318" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7964287793741575" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="210" I2="63.648076551292256" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.02410246523081901" LOG_CI_START="-0.2218085750324746" LOG_EFFECT_SIZE="-0.09885305490082781" METHOD="MH" MODIFIED="2009-11-09 22:52:48 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.026524232129489844" P_Q="0.0" P_Z="0.11508105468178033" Q="0.0" RANDOM="YES" SCALE="31.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09804658660714101" TOTALS="SUB" TOTAL_1="1008" TOTAL_2="999" WEIGHT="300.0" Z="1.575760300635054">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>PegIFN ribavirin</GROUP_LABEL_1>
<GROUP_LABEL_2>PegIFN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PegIFN ribavirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PegIFN</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.053668916167813" CI_START="0.32522037134549225" DF="0" EFFECT_SIZE="0.996551724137931" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.48482194834713965" LOG_CI_START="-0.48782225863195605" LOG_EFFECT_SIZE="-0.0015001551424082332" MODIFIED="2008-08-07 14:52:59 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9951761069226698" STUDIES="1" TAU2="0.0" TOTAL_1="290" TOTAL_2="289" WEIGHT="99.99999999999999" Z="0.00604589022223187">
<NAME>Anaemia</NAME>
<DICH_DATA CI_END="3.053668916167813" CI_START="0.32522037134549225" EFFECT_SIZE="0.996551724137931" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.48482194834713965" LOG_CI_START="-0.48782225863195605" LOG_EFFECT_SIZE="-0.0015001551424082332" MODIFIED="2008-08-07 14:52:59 +0200" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.5713360218459953" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.3264248498588076" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.258139176516156" CI_END="16.579583995870443" CI_START="0.34680944530784696" DF="1" EFFECT_SIZE="2.3979066556149937" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="125" I2="86.22236394645726" ID="CMP-002.04.02" LOG_CI_END="1.2195736293165165" LOG_CI_START="-0.4599090830838954" LOG_EFFECT_SIZE="0.37983227311631046" MODIFIED="2008-08-07 14:52:31 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.007058065260067581" P_Z="0.3753309334321544" STUDIES="2" TAU2="1.7086487742227496" TOTAL_1="359" TOTAL_2="355" WEIGHT="100.0" Z="0.8865319898529104">
<NAME>Flu like symptoms</NAME>
<DICH_DATA CI_END="1.249423291568628" CI_START="0.8607951440912142" EFFECT_SIZE="1.0370619568264647" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="123" LOG_CI_END="0.09670959774050121" LOG_CI_START="-0.06510019160837685" LOG_EFFECT_SIZE="0.01580470306606217" MODIFIED="2008-08-06 17:04:50 +0200" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.09504787123490613" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.009034097826287297" WEIGHT="56.660877304705686"/>
<DICH_DATA CI_END="30.1669930580208" CI_START="1.7060045811129991" EFFECT_SIZE="7.173913043478261" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.4795320233539566" LOG_CI_START="0.23198019303867026" LOG_EFFECT_SIZE="0.8557561081963134" ORDER="86" O_E="0.0" SE="0.732818120608356" STUDY_ID="STD-ICOS-2005" TOTAL_1="69" TOTAL_2="66" VAR="0.5370223978919632" WEIGHT="43.33912269529432"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4955516232259216" CI_END="1.027278023326369" CI_START="0.5682740095031031" DF="1" EFFECT_SIZE="0.7640519623625726" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="79" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.011687997303104367" LOG_CI_START="-0.24544220632990044" LOG_EFFECT_SIZE="-0.11687710451339806" MODIFIED="2008-08-07 14:52:27 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.481461298440789" P_Z="0.07478487597248869" STUDIES="2" TAU2="0.0" TOTAL_1="359" TOTAL_2="355" WEIGHT="100.0" Z="1.7817814650085728">
<NAME>Depression</NAME>
<DICH_DATA CI_END="1.0112522975451477" CI_START="0.552411479783406" EFFECT_SIZE="0.7474137931034482" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="76" LOG_CI_END="0.0048595213298921825" LOG_CI_START="-0.2577373048313085" LOG_EFFECT_SIZE="-0.1264388917507082" MODIFIED="2008-08-06 17:04:58 +0200" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.15425067556234298" STUDY_ID="STD-APRICOT-2004" TOTAL_1="290" TOTAL_2="289" VAR="0.023793270911439197" WEIGHT="95.8798270613643"/>
<DICH_DATA CI_END="5.482960070808411" CI_START="0.2966552780455687" EFFECT_SIZE="1.2753623188405796" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7390150831822743" LOG_CI_START="-0.5277479203564477" LOG_EFFECT_SIZE="0.10563358141291328" MODIFIED="2008-08-06 17:04:23 +0200" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.7441028588566434" STUDY_ID="STD-ICOS-2005" TOTAL_1="69" TOTAL_2="66" VAR="0.5536890645586298" WEIGHT="4.120172938635697"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-09 22:56:45 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3">
<NAME>High dose versus low dose-interferon</NAME>
<DICH_OUTCOME CHI2="3.4518031503017053" CI_END="2.4887681344635113" CI_START="0.8682693975056998" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.470007213806115" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="20" I2="42.059268361662234" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.39598443754324775" LOG_CI_START="-0.0613455055863484" LOG_EFFECT_SIZE="0.16731946597844968" METHOD="MH" MODIFIED="2009-09-23 11:34:28 +0200" MODIFIED_BY="Alfonso Iorio" NO="1" P_CHI2="0.1780127866300082" P_Q="0.0" P_Z="0.15152913974741516" Q="0.0" RANDOM="NO" SCALE="6.1550909963666784" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="178" WEIGHT="100.00000000000003" Z="1.4341511294278235">
<NAME>Sustained virological response</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.802722617660403" CI_START="0.17306470794931075" EFFECT_SIZE="0.5585585585585585" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.25592890759487835" LOG_CI_START="-0.7617914861716856" LOG_EFFECT_SIZE="-0.2529312892884036" ORDER="95" O_E="0.0" SE="0.5978139970956774" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="0.35738157512351054" WEIGHT="32.64524721158649"/>
<DICH_DATA CI_END="4.035426380401881" CI_START="0.6843401844569948" EFFECT_SIZE="1.661807580174927" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6058894287415266" LOG_CI_START="-0.1647279574820849" LOG_EFFECT_SIZE="0.22058073562972086" MODIFIED="2008-08-18 10:57:16 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="96" O_E="0.0" SE="0.4526644672853326" STUDY_ID="STD-SHIRT-2003" TOTAL_1="49" TOTAL_2="57" VAR="0.20490511994271393" WEIGHT="32.35669496698297"/>
<DICH_DATA CI_END="5.004713617197793" CI_START="0.9175023959242866" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6993792310602608" LOG_CI_START="-0.037392792977411875" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2008-08-26 09:25:45 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="94" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="0.1873015873015873" WEIGHT="34.99805782143056"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.86987634414043" CI_END="2.369013296793279" CI_START="0.9976071823934953" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.53731736478408" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.37456749833683933" LOG_CI_START="-0.0010404327626402465" LOG_EFFECT_SIZE="0.18676353278709953" METHOD="MH" MODIFIED="2009-11-09 22:54:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.39261019935087793" P_Q="0.0" P_Z="0.051282791577028114" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="178" WEIGHT="100.0" Z="1.9491057966570602">
<NAME>End of treatment</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1398399770563755" CI_END="3.494026979551967" CI_START="1.0849920254514955" DF="1" EFFECT_SIZE="1.9470468431771895" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.5433262541172343" LOG_CI_START="0.03542654618902892" LOG_EFFECT_SIZE="0.28937640015313165" MODIFIED="2008-08-26 09:22:29 +0200" MODIFIED_BY="Emanuela Marchesini" NO="1" P_CHI2="0.708440262610041" P_Z="0.025523689042239714" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="121" WEIGHT="52.73471538290069" Z="2.2333831401067132">
<NAME>48 wks</NAME>
<DICH_DATA CI_END="4.383413824347324" CI_START="0.6405712722022583" EFFECT_SIZE="1.6756756756756757" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6418124729689889" LOG_CI_START="-0.19343254210647126" LOG_EFFECT_SIZE="0.22418996543125888" MODIFIED="2008-08-18 10:12:30 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="78" O_E="0.0" SE="0.49062705638483084" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="0.24071490845684398" WEIGHT="19.869495612701886"/>
<DICH_DATA CI_END="4.412923060800573" CI_START="1.009940590862751" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6447263556001406" LOG_CI_START="0.004295827426867537" LOG_EFFECT_SIZE="0.3245110915135041" MODIFIED="2008-08-26 09:22:29 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="79" O_E="0.0" SE="0.37619206243122316" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="0.14152046783625732" WEIGHT="32.8652197701988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0716579671706272" CI_START="0.5632097052963927" DF="0" EFFECT_SIZE="1.0801749271137027" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.31631805453263123" LOG_CI_START="-0.2493298699874782" LOG_EFFECT_SIZE="0.0334940922725765" MODIFIED="2008-08-18 10:54:35 +0200" MODIFIED_BY="Emanuela Marchesini" NO="2" P_CHI2="1.0" P_Z="0.816449984065079" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="57" WEIGHT="47.26528461709932" Z="0.23211334013045584">
<NAME>24 wks</NAME>
<DICH_DATA CI_END="2.0716579671706272" CI_START="0.5632097052963927" EFFECT_SIZE="1.0801749271137027" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.31631805453263123" LOG_CI_START="-0.2493298699874782" LOG_EFFECT_SIZE="0.0334940922725765" MODIFIED="2008-08-18 10:54:35 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="92" O_E="0.0" SE="0.3322643908654965" STUDY_ID="STD-SHIRT-2003" TOTAL_1="49" TOTAL_2="57" VAR="0.11039962543721943" WEIGHT="47.26528461709932"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-09 22:54:52 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="127" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-18 10:25:04 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-26 09:27:54 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="83" O_E="0.0" SE="0.0" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0520404163443415" CI_END="1.3870859800240152" CI_START="0.6710418515566742" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9647760073217094" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.1421033821206241" LOG_CI_START="-0.17325039289611469" LOG_EFFECT_SIZE="-0.015573505387745304" METHOD="MH" MODIFIED="2009-11-09 22:56:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.9148507413178837" P_Q="0.0" P_Z="0.8465026848727439" Q="0.0" RANDOM="NO" SCALE="188.3404005880945" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="420" WEIGHT="100.0" Z="0.1935826496537174">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.15685624544086496" CI_END="1.5268594263574804" CI_START="0.6950983554663297" DF="2" EFFECT_SIZE="1.03020263845971" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.18379905462843937" LOG_CI_START="-0.1579537389867556" LOG_EFFECT_SIZE="0.01292265782084188" MODIFIED="2009-05-28 10:59:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.9245685361771446" P_Z="0.8821661725060681" STUDIES="3" TAU2="0.0" TOTAL_1="176" TOTAL_2="178" WEIGHT="78.98059277685213" Z="0.14822377102148032">
<NAME>All</NAME>
<DICH_DATA CI_END="1.8765872519914129" CI_START="0.4526229262929866" EFFECT_SIZE="0.9216216216216216" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.2733687617560143" LOG_CI_START="-0.34426345190500884" LOG_EFFECT_SIZE="-0.03544734507449726" MODIFIED="2008-08-18 10:26:32 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="84" O_E="0.0" SE="0.3628002196332506" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="0.13162399936593486" WEIGHT="23.00941027386009"/>
<DICH_DATA CI_END="2.7689481007548733" CI_START="0.3590452258020406" EFFECT_SIZE="0.9970845481049563" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.44231481570693054" LOG_CI_START="-0.4448508436802014" LOG_EFFECT_SIZE="-0.0012680139866354553" MODIFIED="2008-08-21 13:21:53 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="274" O_E="0.0" SE="0.5211254998648411" STUDY_ID="STD-SHIRT-2003" TOTAL_1="49" TOTAL_2="57" VAR="0.2715717866093806" WEIGHT="13.683617675357286"/>
<DICH_DATA CI_END="1.869564044124917" CI_START="0.6472097084892122" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.27174034701558925" LOG_CI_START="-0.18895497669913913" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2008-08-26 09:28:02 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="85" O_E="0.0" SE="0.2706147136286629" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="0.07323232323232323" WEIGHT="42.28756482763476"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7120442266236902" CI_END="2.0905703024312055" CI_START="0.15066363832892618" DF="1" EFFECT_SIZE="0.5612244897959184" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.32026477673912973" LOG_CI_START="-0.8219915491356317" LOG_EFFECT_SIZE="-0.250863386198251" MODIFIED="2009-05-28 10:58:43 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.3987664897520007" P_Z="0.3892941272550471" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="121" WEIGHT="12.188768685612372" Z="0.860898190450894">
<NAME>Flu-like symptoms</NAME>
<DICH_DATA CI_END="3.859590647254731" CI_START="0.18187738199958725" EFFECT_SIZE="0.8378378378378378" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.586541245328271" LOG_CI_START="-0.7402213057937157" LOG_EFFECT_SIZE="-0.07684003023272232" MODIFIED="2008-08-21 13:22:32 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="272" O_E="0.0" SE="0.7793468901096036" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="0.6073815751235105" WEIGHT="6.902823082158027"/>
<DICH_DATA CI_END="4.108222688821181" CI_START="0.009736570539090633" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6136539767716357" LOG_CI_START="-2.0115939854436733" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2008-08-26 09:28:08 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="273" O_E="0.0" SE="1.542083648192269" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="2.378021978021978" WEIGHT="5.285945603454345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7227835719957323" CI_END="3.6049949179061205" CI_START="0.24334472494523643" DF="1" EFFECT_SIZE="0.9366197183098592" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.5569046568149807" LOG_CI_START="-0.613778063646922" LOG_EFFECT_SIZE="-0.028436703415970647" MODIFIED="2009-05-28 10:58:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.3952323873240825" P_Z="0.9241418346367973" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="121" WEIGHT="8.830638537535494" Z="0.09521779652194565">
<NAME>Depression</NAME>
<DICH_DATA CI_END="4.403777306809588" CI_START="0.03985057563124951" EFFECT_SIZE="0.4189189189189189" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6438253491577813" LOG_CI_START="-1.3995654009511884" LOG_EFFECT_SIZE="-0.3778700258967035" MODIFIED="2008-08-21 13:22:46 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="270" O_E="0.0" SE="1.2002978415613534" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="1.440714908456844" WEIGHT="4.601882054772018"/>
<DICH_DATA CI_END="8.763909837787892" CI_START="0.2567347270391276" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9426979009342388" LOG_CI_START="-0.5905153828228764" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-08-26 09:28:18 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="271" O_E="0.0" SE="0.9006170724070864" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="0.8111111111111111" WEIGHT="4.228756482763476"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3540617646770847" CI_END="2.4522501408130832" CI_START="0.7039613523756532" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3138832997987926" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.38956476814409713" LOG_CI_START="-0.1524511830606136" LOG_EFFECT_SIZE="0.11855679254174176" METHOD="MH" MODIFIED="2009-11-09 22:56:45 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" P_CHI2="0.551823039201078" P_Q="0.0" P_Z="0.39121407235981764" Q="0.0" RANDOM="NO" SCALE="6.1550909963666784" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="127" TOTAL_2="121" WEIGHT="100.0" Z="0.857417730928142">
<NAME>Losses to follow-up</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.557875323663116" CI_START="0.45365897392693233" EFFECT_SIZE="1.0772200772200773" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.40787937221272375" LOG_CI_START="-0.34327049382803226" LOG_EFFECT_SIZE="0.03230443919234575" MODIFIED="2008-08-26 12:20:07 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="108" O_E="0.0" SE="0.44122914956414416" STUDY_ID="STD-ROCO-2003" TOTAL_1="37" TOTAL_2="31" VAR="0.1946831624250979" WEIGHT="52.11267605633803"/>
<DICH_DATA CI_END="3.870753810613104" CI_START="0.6379604273284702" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5877955500086205" LOG_CI_START="-0.19520625972068423" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2008-08-26 12:20:11 +0200" MODIFIED_BY="Emanuela Marchesini" ORDER="110" O_E="0.0" SE="0.4599391389564619" STUDY_ID="STD-Sulkowski-2004" TOTAL_1="90" TOTAL_2="90" VAR="0.21154401154401156" WEIGHT="47.887323943661976"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-11-09 22:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-11-09 22:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-11-09 22:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT4AAAKOCAIAAACweOKPAAAfN0lEQVR42u3du24l1dbF8S2REDjo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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-08-27 18:04:17 +0200" MODIFIED_BY="Davide Matino"/>
<APPENDICES MODIFIED="2009-11-09 14:05:52 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-11-09 14:05:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-23 13:38:41 +0200" MODIFIED_BY="Sarah Louise Klingenberg">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-09 14:05:52 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="6">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TD>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Time span of search</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Search Strategy</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>May 2009.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>'chronic hepatitis C' AND (HIV OR 'human immunodeficiency virus') AND (therap* OR intervention* OR treat*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 1, 2009.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 chronic hepatitis C<BR/>#2 chronic next hepatitis next c<BR/>#3 (#1 or #2)<BR/>#4 HIV<BR/>#5 Human next immunodeficiency next virus<BR/>#6 (#4 or #5)<BR/>#7 (#3 and #6)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (WinSPIRS SilverPlatter)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1950 to May 2009.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "Therapeutics"/all subheadings<BR/>#2 explode "Intervention-Studies"/all subheadings<BR/>#3 therap* or intervention* or treat*<BR/>#4 #1 or #2 or #3<BR/>#5 explode "Hepatitis-C-Chronic"/all subheadings<BR/>#6 chronic hepatitis C<BR/>#7 #5 or #6<BR/>#8 explode "HIV"/all subheadings<BR/>#9 hiv<BR/>#10 human immunodeficiency virus<BR/>#11 #8 or #9 or #10<BR/>#12 #4 and #7 and #11<BR/>#13 random* or blind* or placebo or meta-analysis<BR/>#14 #12 and #13</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (WinSPIRS SilverPlatter)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to May 2009.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "therapy"/all subheadings<BR/>#2 therap* or intervention* or treat*<BR/>#3 #1 or #2<BR/>#4 explode "chronic-hepatitis"/all subheadings<BR/>#5 explode "hepatitis-C"/all subheadings<BR/>#6 chronic hepatitis C<BR/>#7 #4 or #5 or #6<BR/>#8 explode "Human-immunodeficiency-virus"/all subheadings<BR/>#9 hiv<BR/>#10 human immunodeficiency virus<BR/>#11 #8 or #9 or #10<BR/>#12 #3 and #7 and #11<BR/>#13 random* or blind* or placebo or meta-analysis<BR/>#14 #12 and #13<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (http://apps.isiknowledge.com)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to January 2009.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 6 #5 AND #4<BR/># 5 TS=(random* or blind* or placebo or meta-analysis)<BR/># 4 #3 AND #2 AND #1<BR/># 3 TS=(human immunodeficiency virus OR HIV)<BR/># 2 TS=(chronic hepatitis C)<BR/># 1 TS=(therap* or intervention* or treat*)</P>
</TD>
</TR>
</TABLE>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-08-27 18:04:17 +0200" MODIFIED_BY="Davide Matino"/>
</COCHRANE_REVIEW>